0001140361-16-050280.txt : 20160204 0001140361-16-050280.hdr.sgml : 20160204 20160204140122 ACCESSION NUMBER: 0001140361-16-050280 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160204 DATE AS OF CHANGE: 20160204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHARPS COMPLIANCE CORP CENTRAL INDEX KEY: 0000898770 STANDARD INDUSTRIAL CLASSIFICATION: HAZARDOUS WASTE MANAGEMENT [4955] IRS NUMBER: 742657168 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34269 FILM NUMBER: 161387870 BUSINESS ADDRESS: STREET 1: 9220 KIRBY DRIVE STREET 2: STE 500 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 713-432-0300 MAIL ADDRESS: STREET 1: 9220 KIRBY DRIVE STREET 2: STE 500 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: US MEDICAL SYSTEMS INC DATE OF NAME CHANGE: 19970128 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL POLYMERS TECHNOLOGIES INC DATE OF NAME CHANGE: 19930916 10-Q 1 form10q.htm SHARPS COMPLIANCE CORP. 10-Q 12-31-2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2015

☐	TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 001-34269

SHARPS COMPLIANCE CORP.

(Exact name of registrant as specified in its charter)

Delaware	74-2657168
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

9220 Kirby Drive, Suite 500, Houston, Texas	77054
(Address of principal executive offices)	(Zip Code)

(713) 432-0300

(Registrant’s telephone number, including area code)

Indicate by check mark if the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Securities Exchange Act of 1934.

Large Accelerated Filer ☐	Accelerated Filer ☐	Non-accelerated Filer ☐	Smaller reporting company ☒
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes ☐ No ☒

As of February 1, 2016, there were 15,479,286 outstanding shares of the Registrant's common stock, par value $0.01 per share.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

PART I	FINANCIAL INFORMATION	PAGE

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets as of December 31, 2015 and June 30, 2015	3

	Condensed Consolidated Statements of Income for the three months ended December 31, 2015 and 2014	4

	Condensed Consolidated Statements of Income for the six months ended December 31, 2015 and 2014	5

	Condensed Consolidated Statements of Stockholders’ Equity for the six months ended December 31, 2015 and year ended June 30, 2015	6

	Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2015 and 2014	7

	Notes to Condensed Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20

Item 4.	Controls and Procedures	21

Part II	OTHER INFORMATION

Item 1.	Legal Proceedings	21

Item 1A.	Risk Factors	21

Item 2.	Unregistered Sales Of Equity Securities And Use Of Proceeds.	21

Item 6.	Exhibits	22

	SIGNATURES	23

Table of Contents

PART I

FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and par value)

	December 31,			June 30,
	2015			2015
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	14,459		$	15,157
Accounts receivable, net of allowance for doubtful accounts of $53 and $34, respectively		6,306			6,647
Inventory		3,787			2,738
Prepaid and other current assets		612			733
TOTAL CURRENT ASSETS		25,164			25,275

PROPERTY, PLANT AND EQUIPMENT, net		4,266			3,810

GOODWILL		1,039			-

INTANGIBLE ASSETS, net of accumulated amortization of $427 and $385, respectively		1,204			666
TOTAL ASSETS	$	31,673		$	29,751

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	1,723		$	1,770
Accrued liabilities		2,407			1,917
Deferred revenue		2,264			1,877
TOTAL CURRENT LIABILITIES		6,394			5,564

LONG-TERM DEFERRED REVENUE, net of current portion		511			483

OTHER LONG-TERM LIABILITIES		216			118

TOTAL LIABILITIES		7,121			6,165

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
Common stock, $0.01 par value per share; 20,000,000 shares authorized; 15,740,458 and 15,575,041 shares issued, respectively and 15,481,186 and 15,383,791 shares outstanding, respectively		158			156
Treasury stock, at cost, 259,272 and 191,250 shares repurchased, respectively		(1,349	)		(809	)
Additional paid-in capital		25,013			24,344
Retained earnings (accumulated deficit)		730			(105	)
TOTAL STOCKHOLDERS' EQUITY		24,552			23,586

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	31,673		$	29,751

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In thousands, except per-share data)

	Three-Months Ended December 31,
	2015		2014
REVENUES	$	9,992	$	8,693
Cost of revenues		6,673		5,465
GROSS PROFIT		3,319		3,228

Selling, general and administrative		2,585		2,415
Depreciation and amortization		70		69

OPERATING INCOME		664		744

INTEREST INCOME		9		10
TOTAL INTEREST INCOME		9		10

INCOME BEFORE INCOME TAXES		673		754

INCOME TAX EXPENSE - Current		58		5

TOTAL INCOME TAX EXPENSE		58		5

NET INCOME	$	615	$	749

NET INCOME PER COMMON SHARE
Basic	$	0.04	$	0.05

Diluted	$	0.04	$	0.05

WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME PER COMMON SHARE:

Basic		15,467		15,281
Diluted		16,062		15,423

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In thousands, except per-share data)

	Six-Months Ended December 31,
	2015		2014
REVENUES	$	17,861	$	15,740
Cost of revenues		11,663		10,178
GROSS PROFIT		6,198		5,562

Selling, general and administrative		5,181		4,738
Depreciation and amortization		122		154

OPERATING INCOME		895		670

INTEREST INCOME		18		18
TOTAL INTEREST INCOME		18		18

INCOME BEFORE INCOME TAXES		913		688

INCOME TAX EXPENSE - Current		78		13
TOTAL INCOME TAX EXPENSE		78		13

NET INCOME	$	835	$	675

NET INCOME PER COMMON SHARE
Basic	$	0.05	$	0.04

Diluted	$	0.05	$	0.04

WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME PER COMMON SHARE:

Basic		15,443		15,285
Diluted		15,994		15,428

Table of Contents

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share data)

	Common Stock				Treasury Stock						Additional Paid-in			Retained Earnings (Accumulated			Total Stockholders'
	Shares		Amount		Shares			Amount			Capital			Deficit)			Equity
Balances, June 30, 2014		15,460,940	$	155		(161,801	)	$	(681	)	$	23,695		$	(1,265	)	$	21,904
Exercise of stock options		61,109		-		-			-			139			-			139
Stock-based compensation		-		-		-			-			511			-			511
Issuance of restricted stock		52,992		1		-			-			(1	)		-			-
Shares repurchased		-		-		(29,449	)		(128	)		-			-			(128	)
Net income		-		-		-			-			-			1,160			1,160

Balances, June 30, 2015		15,575,041		156		(191,250	)		(809	)		24,344			(105	)		23,586
Exercise of stock options		112,425		1		-			-			312			-			313
Stock-based compensation		-		-		-			-			358			-			358
Issuance of restricted stock		52,992		1		-			-			(1	)		-			-
Shares repurchased		-		-		(68,022	)		(540	)		-			-			(540	)
Net income		-		-		-			-			-			835			835
Balances, December 31, 2015		15,740,458	$	158		(259,272	)	$	(1,349	)	$	25,013		$	730		$	24,552

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Six-Months Ended December 31,
	2015			2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	835		$	675
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		379			460
Stock-based compensation expense		358			257
Changes in operating assets and liabilities, net of effects of business acqusition:
Restricted cash		-			111
Accounts receivable		434			367
Legal settlement receivable		-			1,538
Inventory		(943	)		(888	)
Prepaid and other current assets		121			(445	)
Accounts payable and accrued liabilities		(105	)		804
Deferred revenue		415			107
NET CASH PROVIDED BY OPERATING ACTIVITIES		1,494			2,986

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(761	)		(237	)
Payments for acquisition, net of cash acquired		(1,204	)		-
NET CASH USED IN INVESTING ACTIVITIES		(1,965	)		(237	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of stock options		313			21
Shares repurchased		(540	)		(128	)
NET CASH USED IN FINANCING ACTIVITIES		(227	)		(107	)

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(698	)		2,642

CASH AND CASH EQUIVALENTS, beginning of period		15,157			13,717

CASH AND CASH EQUIVALENTS, end of period	$	14,459		$	16,359

SUPPLEMENTAL CASH FLOW DISCLOSURES:
Income taxes paid	$	85		$	10

NON-CASH INVESTING ACTIVITIES:
Unpaid consideration related to acquisitions	$	529		$	-

Transfer of equipment to inventory	$	106		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 - ORGANIZATION AND BACKGROUND

The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com, Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.), Sharps Safety, Inc., Alpha Bio/Med Services LLC and Bio-Team Mobile LLC (collectively, “Sharps” or the “Company”). All significant intercompany accounts and transactions have been eliminated upon consolidation.

NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of December 31, 2015, the results of its operations for the three and six months ended December 31, 2015 and 2014, cash flows for the six months ended December 31, 2015 and 2014 and stockholders’ equity for the six months ended December 31, 2015 and the year ended June 30, 2015. The results of operations for the three and six months ended December 31, 2015 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2016. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended June 30, 2015.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition: The Company recognizes revenue from product sales and services when goods are shipped or delivered, services provided, and title and risk of loss pass to the customer except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse. During the three and six months ended December 31, 2015, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $1.9 million and $2.5 million, respectively. During the three and six months ended December 31, 2014, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.8 million and $1.6 million, respectively. As of December 31, 2015 and June 30, 2015, $2.9 million and $1.6 million, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program.

Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ and various other solutions like the TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service.

In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting. The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price. The selling price for the transportation revenue and the treatment revenue utilizes third party evidence. The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities.

Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container. Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned. Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.

Table of Contents

Income Taxes: Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of a valuation allowance requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under generally accepted accounting principles, the valuation allowance has been recorded to reduce our deferred tax assets to an amount that is more likely than not to be realized and is based on the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes.

Accounts Receivable: Accounts receivable consist primarily of amounts due to the Company from our normal business activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer. The Company maintains an allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past collection history and specific risks identified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.

Stock-Based Compensation: Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).

NOTE 4 – RECENTLY ISSUED ACCOUNTING STANDARDS

In May 2014, guidance for revenue recognition was issued which supersedes the revenue recognition requirements currently followed by the Company. The new guidance provides for a single five-step model to be applied in determining the amount and timing of the recognition of revenue related to contracts with customers. The new standard also requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. The guidance is effective for annual reporting periods beginning after December 15, 2017 (effective July 1, 2018 for the Company). The Company is evaluating the impact that the new accounting guidance will have on its consolidated financial statements and related disclosures and has not yet determined the method by which it will adopt the standard.

In July 2015, guidance for inventory measurement was issued, which supersedes the policy currently followed by the Company. The new guidance requires the Company to measure inventory at the lower of cost or net realizable value. The provisions of the new guidance are effective for annual reporting periods beginning after December 15, 2016 (effective July 1, 2017 for the Company) including interim periods within the reporting period. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

In September 2015, guidance for business combinations was issued, which simplifies the accounting for measurement-period adjustments. The new guidance eliminates the requirement to restate prior period financial statements for measurement period adjustments following a business combination and requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. The provisions of the new guidance are effective for annual reporting periods beginning after December 15, 2015 (effective July 1, 2016 for the Company) including interim periods within the reporting period. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

NOTE 5 - INCOME TAXES

The establishment of valuation allowances and development of projected annual effective tax rates requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under generally accepted accounting principles, the valuation allowance has been recorded to reduce the Company’s net deferred tax asset to an amount that is more likely than not to be realized and is based upon the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes. The Company’s net deferred tax assets have been fully reserved by a tax valuation allowance.

Table of Contents

The Company’s effective tax rate for the six months ended December 31, 2015 and 2014 was 8.5% and 1.9%, respectively, reflecting estimated state income taxes. The Company’s federal tax expense associated with taxable income during the six months ended December 31, 2015 and 2014 was offset by the utilization of net operating loss carryforwards.

NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT

On April 9, 2015, the Company entered into a credit agreement with a commercial bank (“Credit Agreement”). The Credit Agreement, which replaces, in its entirety, the Company’s prior credit agreement, which was executed effective January 28, 2014 with the same commercial bank, provides for a two-year, $9.0 million line of credit facility, the proceeds of which may be utilized as follows: (i) $4.0 million for working capital, letters of credit (up to $500,000) and general corporate purposes and (ii) $5.0 million for acquisitions. Indebtedness under the Credit Agreement is secured by the Company’s accounts receivable and inventory with advances outstanding under the working capital portion of the credit facility at any time limited to a Borrowing Base (as defined in the Credit Agreement) equal to 80% of eligible accounts receivable plus 50% of eligible inventory. Advances under the acquisition portion of the credit facility are limited to 75% of the purchase price of an acquired company and convert to a five-year term note. Borrowings bear interest at WSJ Prime (for the working capital line) and WSJ Prime plus 0.25% (for the acquisition line), which was approximately 3.50% and 3.75%, respectively, as of December 31, 2015. The Company pays a fee of 0.25% per annum on the unused amount of the line of credit. As of December 31, 2015, the Company had no outstanding borrowings other than $0.3 million in letters of credit, which left $8.7 million of credit available under the Credit Agreement.

The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a minimum level of tangible net worth of $12.5 million, minimum liquidity of $7.0 million and a minimum debt service coverage ratio of not less than 1.15 to 1.00. The Credit Agreement, which expires on April 9, 2017, also contains customary events of default which, if uncured, may terminate the Credit Agreement and require immediate repayment of all indebtedness to the lenders. The Company was in compliance with all the financial covenants under the Credit Agreement as of December 31, 2015.

NOTE 7 – STOCK-BASED COMPENSATION

Stock-based compensation cost for options and restricted stock awarded to employees and directors is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant). Stock-based compensation costs from performance-based stock option awards are estimated at the date when key terms and conditions of the performance-based stock award are known (the “service inception date”), and in subsequent reporting periods, trued up at the grant date and recognized as expense over the employee’s requisite period (from the service inception date through the end of the vesting period). During the three and six months ended December 31, 2015 and 2014, stock-based compensation amounts are as follows (in thousands):

	Three-Months Ended				Six-Months Ended
	December 31,				December 31,
	2015		2014		2015		2014
	(Unaudited)				(Unaudited)
Stock-based compensation expense included in:

Cost of revenues	$	10	$	6	$	18	$	10
Selling, general and administrative		207		135		340		247
Total	$	217	$	141	$	358	$	257

NOTE 8 - EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted per share is computed by dividing net income by the weighted average number of common shares after considering the additional dilution related to common stock options, restricted stock and performance-based stock option awards. In computing diluted earnings per share, the outstanding common stock options and performance-based stock option awards are considered dilutive using the treasury stock method.

The Company’s restricted stock awards are treated as outstanding for earnings per share calculations since these shares have full voting rights and are entitled to participate in dividends declared on common shares, if any, and undistributed earnings. As participating securities, the shares of restricted stock are included in the calculation of basic EPS using the two-class method. For the periods presented, the amount of earnings allocated to the participating securities was not material.

Table of Contents

The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):

	Three-Months Ended				Six-Months Ended
	December 31,				December 31,
	2015		2014		2015		2014
	(Unaudited)				(Unaudited)
Net income, as reported	$	615	$	749	$	835	$	675

Weighted average common shares outstanding		15,467		15,281		15,443		15,285
Effect of dilutive stock options		595		142		551		143
Weighted average diluted common shares outstanding		16,062		15,423		15,994		15,428

Net income per common share
Basic	$	0.04	$	0.05	$	0.05	$	0.04
Diluted	$	0.04	$	0.05	$	0.05	$	0.04

Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive		120		392		216		237

NOTE 9 - EQUITY TRANSACTIONS

During the three and six months ended December 31, 2015 and 2014, stock options to purchase shares of the Company’s common stock were exercised as follows:

	Three-Months Ended December 31,				Six-Months Ended December 31,
	2015		2014		2015		2014
	(Unaudited)				(Unaudited)
Options exercised		11,000		10,250		112,425		10,250
Proceeds (in thousands)	$	45	$	21	$	313	$	21
Average exercise price per share	$	3.98	$	2.12	$	2.77	$	2.12

As of December 31, 2015, there was $0.5 million of stock option and restricted stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 2.6 years.

	Three-Months Ended						Six-Months Ended
	December 31,						December 31,
	2015			2014			2015			2014
	(Unaudited)						(Unaudited)
Shares repurchased			68,022			-			68,022			29,449
Cash paid for shares repurchased (in thousands)		$	540		$	-		$	540		$	128
Average price paid per share		$	7.94		$	-		$	7.94		$	4.35

Total shares repurchased under the program are 259,272 shares at a cost of $1.3 million. As of December 31, 2015, approximately $1.7 million remained of the Company’s $3.0 million repurchase program. Sharps purchased all shares with cash resources.

Table of Contents

NOTE 10 – INVENTORY

The components of inventory are as follows (in thousands):

	December 31, 2015		June 30, 2015
	(Unaudited)
Raw materials	$	1,236	$	1,393
Finished goods		2,551		1,345
Total	$	3,787	$	2,738

NOTE 11 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable and accounts payable to approximate their carrying values at December 31, 2015 due to their short-term nature.

NOTE 12 – ACQUISITIONS

Effective on July 17, 2015, the Company acquired Alpha Bio/Med Services LLC, a route-based pickup service located in Pennsylvania for total cash consideration of $0.7 million of which $0.1 million has been withheld for possible settlement amounts through July 2016.

The following amounts represent the fair value of the assets acquired and liabilities assumed:

Accounts receivable	$	51
Fixed assets		70
Intangibles		267
Goodwill		413
Accounts payable and accrued liabilities		(101	)
Total purchase price	$	700

Effective on December 14, 2015, the Company acquired Bio-Team Mobile LLC, a route-based pickup service located in Pennsylvania for total cash consideration of $1.0 million of which $0.1 million has been withheld for possible settlement amounts through December 2016 and $0.3 million of cash consideration that was paid in January 2016.

The following amounts represent the fair value of the assets acquired and liabilities assumed:

Accounts receivable	$	42
Fixed assets		68
Intangibles		313
Goodwill		626
Accounts payable and accrued liabilities		(16	)
Total purchase price	$	1,033

During the three and six months ended December 31, 2015, the Company incurred $0.1 million and $0.2 million, respectively, of acquisition related expenses for investment banking, legal and accounting fees which are included within selling, general and administrative expenses on our condensed consolidated statements of income. The results of operations of the acquired business have been included in the condensed consolidated statements of income from the date of acquisition. The goodwill recorded as of December 31, 2015 will be deductible for income taxes.

Table of Contents

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains certain forward-looking statements and information relating to the Company and its subsidiaries that are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. When used in this report, the words “anticipate”, “believe”, “expect”, “estimate”, “project” and “intend” and words or phrases of similar import, as they relate to the Company or its subsidiaries or Company management, are intended to identify forward-looking statements. Such statements reflect the current risks, uncertainties and assumptions related to certain factors, including without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein. Based upon changing conditions, should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, expected, estimated or intended. The Company does not intend to update these forward-looking statements.

GENERAL

Sharps Compliance Corp. is a leading full-service national provider of comprehensive waste management services including medical, pharmaceutical and hazardous. Our solutions facilitate the proper collection, containment, transportation and treatment of numerous types of healthcare-related materials, including hypodermic needles, lancets and other devices or objects used to puncture or lacerate the skin, or sharps, hazardous waste and unused consumer dispensed medications and over-the-counter drugs. We serve customers in multiple markets such as home health care, retail clinics and immunizing pharmacies, pharmaceutical manufacturers, professional offices (physicians, dentists and veterinarians), assisted living and long-term care facilities (assisted living, continuing care, long-term acute care, memory care and skilled nursing), government (federal, state and local), consumers, commercial and agriculture, as well as distributors to many of the aforementioned markets. We assist our customers in determining which of our solution offerings best fit their needs for the collection, containment, return transportation and treatment of medical waste, used healthcare materials, pharmaceutical waste, hazardous waste and unused dispensed medications. Our differentiated approach provides our customers the flexibility to return and properly treat medical waste, used healthcare materials or unused dispensed medications through a variety of solutions and products transported primarily through the United States Postal Service (“USPS”). For customers with facilities or locations that may generate larger quantities of medical waste, we integrate the route-based pick-up service into our complete offering. The benefits of this comprehensive offering include single point of contact, consolidated billing, integrated manifest and proof of destruction repository in addition to our cost savings. Furthermore, we provide comprehensive tracking and reporting tools that enable our customers to meet complex medical, pharmaceutical and hazardous waste disposal and compliance requirements. We believe the fully-integrated nature of our operations is a key factor leading to our success and continued recurring revenue growth. We continue to take advantage of the many opportunities in all markets served as we educate the market place and as prospective customers become more aware of alternatives to traditional methods of disposal (i.e., route-based pick-up services).

As a leading full-service provider of comprehensive medical waste management services including medical, pharmaceutical and hazardous, our key markets include pharmaceutical manufacturers, home healthcare providers, assisted living/long-term care, retail pharmacies and clinics and the professional market which is comprised of physicians, dentists and veterinary practices. The Company’s flagship product, the Sharps^® Recovery System, is a comprehensive solution for the containment, transportation, treatment and tracking of medical waste and used healthcare materials. In October 2014, the Company launched MedSafe^®, a patent pending solution for the safe collection, transportation and proper disposal of unwanted and expired prescription medications including controlled substances from ultimate users. MedSafehas been designed to meet or exceed the new regulations issued by the Drug Enforcement Administration (“DEA”) implementing the Secure and Responsible Drug Disposal Act of 2010 (the “Act”) which became effective October 9, 2014. In July 2015, the Company augmented its network of medical and hazardous waste service providers with an acquisition of a route-based pickup service in the northeast serving Pennsylvania, Maryland and parts of Ohio. Additionally, the Company has begun to service parts of Texas and Louisiana with route-based pickup service. In December 2015, the Company acquired another route-based pickup service in the northeast which further expanded its operations in Pennsylvania and neighboring states. Our other solutions include TakeAway Medication Recovery System™, ComplianceTRAC^SM, Route-Based Pick-Up Service, Universal Waste Shipback Systems, TakeAway Environmental Return System™, SharpsTracer^®, Sharps Secure^®Needle Disposal System™, Complete Needle™ Collection & Disposal System, Pitch-It IV™ Poles, Trip LesSystem^®, Sharps^® Pump and Asset Return System, Sharps^® MWMS™ (a Medical Waste Management System (“MWMS”)) and Biohazard Spill Clean-up Kit and Recovery System™.

Table of Contents

RESULTS OF OPERATIONS

The following analyzes changes in the consolidated operating results and financial condition of the Company during the three and six months ended December 31, 2015 and 2014. The following table sets forth, for the periods indicated, certain items from the Company's Condensed Consolidated Statements of Income, dollars in thousands and percentages expressed as a percentage of revenue:

	Three-Months Ended December 31,										Six-Months Ended December 31,
	2015		%			2014		%			2015		%			2014		%
	(Unaudited)										(Unaudited)

Revenue	$	9,992		100.0	%	$	8,693		100.0	%	$	17,861		100.0	%	$	15,740		100.0	%

Cost of revenue		6,673		66.8	%		5,465		62.9	%		11,663		65.3	%		10,178		64.7	%
Gross profit		3,319		33.2	%		3,228		37.1	%		6,198		34.7	%		5,562		35.3	%

SG&A expense		2,585		25.9	%		2,415		27.8	%		5,181		29.0	%		4,738		30.1	%
Depreciation and amortization		70		0.7	%		69		0.8	%		122		0.7	%		154		1.0	%

Operating income		664		6.6	%		744		8.6	%		895		5.0	%		670		4.3	%

Interest income		9		0.1	%		10		0.1	%		18		0.1	%		18		0.1	%

Income before income taxes		673		6.7	%		754		8.7	%		913		5.1	%		688		4.4	%
Income tax expense		58		0.6	%		5		0.1	%		78		0.4	%		13		0.1	%

Net income	$	615		6.2	%	$	749		8.6	%	$	835		4.7	%	$	675		4.3	%

THREE MONTHS ENDED DECEMBER 31, 2015 AS COMPARED TO THREE MONTHS ENDED DECEMBER 31, 2014

Total revenues for the three months ended December 31, 2015 of $10.0 million increased by $1.3 million, or 14.9%, over the total revenues for the three months ended December 31, 2014 of $8.7 million. Billings by market are as follows (in thousands):

	Three-Months Ended December 31,
	(Unaudited)
	2015			2014		Variance
BILLINGS BY MARKET:
Retail	$	3,037		$	3,065	$	(28	)
Home Health Care		2,091			1,752		339
Professional		1,861			1,707		154
Pharmaceutical Manufacturer		2,515			1,303		1,212
Assisted Living		518			455		63
Government		242			150		92
Environmental		75			46		29
Other		188			195		(7	)
Subtotal		10,527			8,673		1,854
GAAP Adjustment *		(535	)		20		(555	)
Revenue Reported	$	9,992		$	8,693	$	1,299

*Represents the net impact of the revenue recognition adjustment required to arrive at reported generally accepted accounting principles (“GAAP”) revenue. Customer billings include all invoiced amounts associated with products shipped during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with products returned for treatment and destruction. The difference between customer billings and GAAP revenue is reflected in the Company’s balance sheet as deferred revenue. See Note 3 “Revenue Recognition” in “Notes to Condensed Consolidated Financial Statements”.

This quarter-to-date table contains certain financial information not derived in accordance with GAAP, including customer billings information. The Company believes this information is useful to investors and other interested parties as customer billings represents all invoiced amounts associated with products shipped during the period reported. Such information should not be considered as a substitute for any measures derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included above.

Table of Contents

The increase in billings was primarily attributable to increased billings in the Pharmaceutical Manufacturer ($1.2 million), Home Health Care ($0.3 million), Professional ($0.2 million), and Government ($0.1 million) markets. The increase in Pharmaceutical Manufacturer market billings is primarily due to timing of new inventory builds for existing and new customers. The Company filled orders for new inventory builds for four patient support programs during the three months ended December 31, 2015. The increase in Home Health Care market billings is due to the timing of distributor purchases. The increase in Professional market billings is a result of continued targeted telemarketing initiatives and promotional activities to educate doctors, dentists, veterinarians and other healthcare professionals about the favorable economics and convenience of the Company’s Sharps Recovery System and our new route-based pickup service. The increase in Government market billings was primarily related to increased sales of the Company’s MedSafe solutions to multiple Government agencies. Retail market billings decreased slightly reflecting a decrease in flu shot related orders, partially offset by an increase in TakeAway Medication Recovery System envelopes which were launched by certain retail pharmacies during the quarter.

Cost of revenues for the three months ended December 31, 2015 of $6.7 million was 66.8% of revenues. Cost of revenues for the three months ended December 31, 2014 of $5.5 million was 62.9% of revenues. Gross margin for the three months ended December 31, 2015 of 33.2% (versus 37.1% for the three months ended December 31, 2014) was adversely impacted by a mix of business including a legacy Pharmaceutical Manufacturer patient support program with a lower upfront margin and by operating costs related to the Company’s existing treatment facility.

Selling, general and administrative (“SG&A”) expenses for the three months ended December 31, 2015 and 2014 was $2.6 million and $2.4 million, respectively. SG&A for the three months ended December 31, 2015 included $0.1 million of acquisition related costs associated with the Company’s acquisition of Bio-Team Mobile LLC in December 2015. Without these acquisition related costs, SG&A costs increased 4.0% compared to the prior period due to increased sales, marketing and compensation related spending.

The Company generated operating income of $0.7 million for the three months ended December 31, 2015 consistent with operating income of $0.7 million for the three months ended December 31, 2014. Operating income was positively impacted by higher revenue offset by lower gross margins and increased SG&A expenses.

The Company generated income before income taxes of $0.7 million for the three months ended December 31, 2015 consistent with income before income taxes of $0.8 million for the three months ended December 31, 2014. Income before income taxes was positively impacted by higher revenue offset by lower gross margins and increased SG&A expenses.

The Company’s effective tax rate for the three months ended December 31, 2015 and 2014 was 8.6% and 0.7%, respectively, reflecting estimated state income taxes. The Company’s net deferred tax assets have been fully reserved by a tax valuation allowance.

The Company generated net income of $0.6 million for the three months ended December 31, 2015 compared to net income of $0.7 million for the three months ended December 31, 2014. Net income was adversely impacted by lower gross margin (discussed above).

The Company reported diluted income per share of $0.04 for the three months ended December 31, 2015 versus diluted income per share of $0.05 for the three months ended December 31, 2014. Diluted income per share was adversely impacted by lower gross margin (discussed above).

Table of Contents

SIX MONTHS ENDED DECEMBER 31, 2015 AS COMPARED TO SIX MONTHS ENDED DECEMBER 31, 2014

Total revenues for the six months ended December 31, 2015 of $17.9 million increased by $2.1 million, or 13.5%, over the total revenues for the six months ended December 31, 2014 of $15.7 million. Billings by market are as follows (in thousands):

	Six-Months Ended December 31,
	(Unaudited)
	2015			2014			Variance
BILLINGS BY MARKET:
Retail	$	4,786		$	5,060		$	(274	)
Home Health Care		4,042			3,505			537
Professional		3,572			3,158			414
Pharmaceutical Manufacturer		3,754			2,688			1,066
Assisted Living		1,044			905			139
Government		706			284			422
Environmental		154			140			14
Other		450			428			22
Subtotal		18,508			16,168			2,340
GAAP Adjustment *		(647	)		(428	)		(219	)
Revenue Reported	$	17,861		$	15,740		$	2,121

This year-to-date table contains certain financial information not derived in accordance with GAAP, including customer billings information. The Company believes this information is useful to investors and other interested parties as customer billings represents all invoiced amounts associated with products shipped during the period reported. Such information should not be considered as a substitute for any measures derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included above.

The increase in billings was primarily attributable to increased billings in the Pharmaceutical Manufacturer ($1.1 million), Home Health Care ($0.5 million), Government ($0.4 million), Professional ($0.4 million) and Assisted Living ($0.1 million) markets. The increase was partially offset by decreased billings in the Retail ($0.3 million) market. The increase in Pharmaceutical Manufacturer market billings is primarily due to timing of new inventory builds for existing and new customers. The increase in Home Health Care market billings is due to the timing of distributor purchases. The increase in Government market billings was primarily related to increased sales of the Company’s MedSafe solutions to multiple Government agencies. The increase in Professional market billings is a result of continued targeted telemarketing initiatives and promotional activities to educate doctors, dentists, veterinarians and other healthcare professionals about the favorable economics and convenience of the Company’s Sharps Recovery System and our new route-based pickup service. The increase in Assisted Living market billings is a result of increased sales focus as well as our new route-based pickup service. The decrease in Retail market billings is primarily due to a decrease in flu shot related orders related to a delay in the peak of flu season partially offset by an increase in TakeAway Medication Recovery System envelopes which were launched by certain retail pharmacies during the year to date period.

Cost of revenues for the six months ended December 31, 2015 of $11.7 million was 65.3% of revenues. Cost of revenues for the six months ended December 31, 2014 of $10.2 million was 64.7% of revenues. The lower gross margin for the six months ended December 31, 2015 of 34.7% (versus 35.3% for the six months ended December 31, 2014) was due to a mix of business and operating costs related to the Company’s existing treatment facility.

Selling, general and administrative (“SG&A”) expenses for the six months ended December 31, 2015 and 2014 was $5.2 million and $4.7 million, respectively. SG&A for the six months ended December 31, 2015 included $0.2 million of acquisition related costs associated with the Company’s acquisitions of Alpha Bio/Med in July 2015 and Bio-Team Mobile in December 2015. Without these acquisition related costs, SG&A costs increased 6.2% compared to the prior period due to increased sales, marketing and compensation related spending.

Table of Contents

The Company generated operating income of $0.9 million for the six months ended December 31, 2015 compared to $0.7 million for the six months ended December 31, 2014. The operating income increased mainly due to the increase in revenues (discussed above).

The Company generated income before income taxes of $0.9 million for the six months ended December 31, 2015 versus income before income taxes of $0.7 million for the six months ended December 31, 2014. Income before income taxes was positively impacted by improvement in operating income (discussed above).

The Company’s effective tax rate for the six months ended December 31, 2015 and 2014 was 8.5% and 1.9%, respectively, reflecting estimated state income taxes. The Company’s net deferred tax assets have been fully reserved by a tax valuation allowance.

The Company generated net income of $0.8 million for the six months ended December 31, 2015 compared to $0.7 million for the six months ended December 31, 2014. Net income was positively impacted by improvement in operating income (discussed above).

The Company reported diluted income per share of $0.05 for the six months ended December 31, 2015 versus diluted income per share of $0.04 for the six months ended December 30, 2014. Diluted income per share was positively impacted by improvement in net income (discussed above).

PROSPECTS FOR THE FUTURE

The Company continues to focus on core markets and solution offerings that fuel growth. Markets served are professional offices, retail pharmacies and clinics, assisted living and long-term care facilities, home healthcare, government, pharmaceutical manufacturers and other commercial organizations that require cost-effective services for managing medical, pharmaceutical and hazardous waste.

The Company believes its growth opportunities are supported by the following:

A large professional market that consists of dentists, veterinarians, clinics, private practice physicians, urgent care facilities, ambulatory surgical centers and others such as acupuncture and tattoo services. This regulated market consists of small to medium quantity generators of medical, pharmaceutical and hazardous waste where we can offer a lower cost to service with solutions to match individual facility needs. The Company addresses this market from two directions: (i) field sales which focuses on larger-dollar and nationwide opportunities where we can integrate the route-based pickup service along with our mailback solutions to create a comprehensive medical waste management offering and (ii) inside and online sales which focus on the individual or small group professional offices.

The shift of healthcare from traditional settings to the retail pharmacy and clinic markets, where the Company focuses on driving increased promotion of the Sharps Recovery System. The number of U.S. retail clinics is projected to increase significantly, as much as 20%-25% per year, driven by the increasing demand of newly insured patients under healthcare reform, as well as patients looking for more convenient care and retail pharmacies increasing the variety and volume of healthcare services they provide. According to the Centers for Disease Control ("CDC"), 25% of flu shots for adults were administered in a retail clinic with the trend expected to increase. In addition to the continued growth in the flu shot business, there are also growth opportunities for more primary care in the retail or alternative site setting and correspondingly growth opportunities for the Company based on its significant presence in the retail market. A recent study shows that Americans visit retail clinics 10 million times a year, which represents only 2% of "all primary care patient encounters."

The passage of new regulations for ultimate user medication disposal allows the Company to offer new solutions (MedSafe and TakeAway Medication Recovery System envelopes) that meet the regulations for ultimate user controlled substances disposal (Schedules II-V) to retail pharmacies. Additionally, with the new regulations, the Company is able to provide the MedSafe and TakeAway Medication Recovery Systems to assisted living and hospice to address a long standing issue within long-term care.

The changing demographics of the U.S. population - one out of five Americans will be 65 years or older by 2030, which will increase the need for cost-effective medical waste management solutions, especially in the long-term care and home healthcare markets. With multiple solutions for managing regulated healthcare-related waste, the Company delivers value as a single-source provider with blended mailback and route-based pickup services matched to on the waste volumes of each facility.

Local, state and federal agencies have growing needs for solutions to manage medical and pharmaceutical waste — the Company's Sharps Recovery System is ideal for as-needed disposal of sharps and other small quantities of medical waste generated within government buildings, schools and communities. The Company also provides TakeAway Medication Recovery System envelopes and MedSafe solutions to government agencies in need of proper and regulatory compliant medication disposal.

Table of Contents

With an increased number of self-injectable medication treatments and local regulations, the Company believes its flagship product, the Sharps Recovery System, continues to offer the best option for proper sharps disposal at an affordable price. The Company delivers premium services to pharmaceutical manufacturers that sell high-dollar, self-injectable medications, which include data management, compliance reporting, fulfillment, proper containment with disposal, branding and conformity with applicable regulations. In addition, the Company provides self-injectors with online and retail purchase options of sharps mailback systems, such as the Sharp Recovery System and Complete Needle Collection & Disposal System, respectively.

A heightened interest by many commercial companies who are looking to improve workplace safety with proper sharps disposal and unused medication disposal solutions — the Company offers a variety of services to meet these needs, including the Sharps Secure Needle Disposal System, Sharps Recovery System, Biohazard Spill Kits and TakeAway Medication Recovery System envelopes.

In July 2015, the Company augmented its network of medical and hazardous waste service providers with an acquisition of a route-based pickup service in the northeast serving Pennsylvania, Maryland and parts of Ohio. Additionally, the Company has begun to service parts of Texas and Louisiana with route-based pickup service. In December 2015, the Company acquired another route-based pickup service in the northeast which further expanded its operations in Pennsylvania and neighboring states. With the addition of these route-based pickup regions and the network of medical and hazardous waste service providers servicing the entire U.S., the Company offers customers a blended product portfolio to effectively manage multi-site and multi-sized locations, including those that generate larger quantities of waste. The network has had a significant positive impact on our pipeline of sales opportunities — over 60% of this pipeline is attributable to opportunities providing comprehensive waste management service offerings where both the mailback and pickup service are integrated into the offering.

The Company has new solution offerings that include ultimate user medication disposal (MedSafe and TakeAway Medication Recovery System) and mailback services for DEA registrant expired inventory of controlled substances (TakeAway Medication Recovery System DEA Reverse Distribution for Registrants).

The Company's strong financial position with a cash balance of $14.5 million and no debt as of December 31, 2015.

LIQUIDITY AND CAPITAL RESOURCES

Cash Flow

Cash flow is primarily influenced by demand for products and services, operating margins and related working capital needs as well as more strategic activities including acquisitions, stock repurchases and fixed asset additions. Cash and cash equivalents decreased by $0.7 million to $14.5 million at December 31, 2015 from $15.2 million at June 30, 2015.

Working capital decreased by $0.9 million to $18.8 million at December 31, 2015 from $19.7 million at June 30, 2015. The decrease is primarily attributed to a decrease in cash and cash equivalents (discussed above) and:

Accounts receivable decreased by $0.4 million, net of assets acquired, to $6.3 million at December 31, 2015 from $6.6 million at June 30, 2015. The decrease is due to timing of billings and collections.

Inventory increased by $1.0 million to $3.8 million at December 31, 2015 from $2.7 million at June 30, 2015. The increase in inventory is due to timing of sales and adjustment of inventory levels to facilitate customer orders as well as transfers of Medsafe equipment to inventory of $0.1 million.

Accounts payable and accrued liabilities decreased by $0.1 million, net of assets acquired and unpaid consideration, to $4.1 million at December 31, 2015 from $3.7 million at June 30, 2015. The decrease is the result of the timing of payments. Accounts payable includes $0.5 million of unpaid consideration related to acquisitions.

Deferred revenue increased by $0.4 million to $2.8 million at December 31, 2015 from $2.4 million at June 30, 2015. The increase is due to the increase in billings for the period.

Property, plant and equipment, increased $0.5 million to $4.3 million at December 31, 2015 from $3.8 million at June 30, 2015. The increase is mainly attributable to capital expenditures of $0.8 million of property, plant and equipment, net of assets acquired, offset in part by depreciation expense of $0.3 million and $0.1 million of transfers of equipment to inventory. Capital expenditures are attributable primarily to investment in Medsafe assets of $0.3 million, treatment facility improvements and pickup related assets acquired of $0.3 million, $0.1 million of assets acquired related to acquisitions and computer and software assets of $0.1 million.

Table of Contents

The Company acquired Alpha Bio/Med Services, LLC and Bio-Team Mobile LLC for $0.7 million and $1.0 million, respectively in the six months ended December 31, 2015 of which $0.5 million is unpaid consideration.

Stockholders’ equity increased by $1.0 million to $24.6 million at December 31, 2015 from $23.6 million at June 30, 2015. This increase is primarily attributable to the net income for the six months ended December 31, 2015 of $0.8 million, proceeds from the exercise of stock options of $0.3 million and stock-based compensation expense of $0.4 million, offset by stock repurchases of $0.5 million.

Off-Balance Sheet Arrangements

The Company was not a party to any off-balance sheet transactions as defined in Item 303 of Regulation S-K for the six months ended December 31, 2015 and the year-ended June 30, 2015.

Credit Facility

Management believes that the Company’s current cash resources (cash on hand) will be sufficient to fund operations for the twelve months ending December 31, 2016.

CRITICAL ACCOUNTING ESTIMATES

Table of Contents

RECENTLY ISSUED ACCOUNTING STANDARDS

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company does not have exposure to significant financial market risk including commodity price risk, foreign currency exchange risk or interest rate risk. Management does not use derivative instruments. The Company has limited exposure to changes in interest rates due to its lack of indebtedness. The Company maintains a credit agreement under which we may borrow funds in the future. The Company does not currently foresee any borrowing needs.

Table of Contents

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures”, as such term is defined in Rule 13a-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including, the Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”) as appropriate, to allow timely decisions regarding required disclosure.

The Company conducted an evaluation (the “Evaluation”), under the supervision and with the participation of the CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls”) as of December 31, 2015, pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based upon this Evaluation, the CEO and CFO concluded that our Disclosure Controls were effective as of December 31, 2015.

Changes in Internal Control over Financial Reporting

During the three months ended December 31, 2015, there were no changes in the Company’s internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act), that have materially affected, or are reasonably likely to materially affect the Company’s internal control over financial reporting.

CEO and CFO Certifications

Appearing immediately following the Signatures section of this report are certifications of the CEO and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This item of this Quarterly Report on Form 10-Q, which you are currently reading, is the information concerning the Evaluation referred to in the Section 302 Certification and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

PART II – OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

The Company is involved in legal proceedings and litigation in the ordinary course of business. In the opinion of management, the outcome of such matters will not have a material adverse effect on the Company’s consolidated financial position or consolidated results of operations.

ITEM 1A.

RISK FACTORS

Refer to Item 1A. Risk Factors in the Company’s annual report on Form 10-K for the year ended June 30, 2015 for the Company’s risk factors. During the six months ended December 31, 2015, there have been no changes to the Company’s risk factors.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Recent Sales of Unregistered Securities.

None.

Table of Contents

Issuer Purchases of Equity Securities.

On January 7, 2013, the Company announced that its Board of Directors approved a stock repurchase program effective January 3, 2013, authorizing the Company to repurchase in the aggregate up to $3.0 million of its outstanding common stock over a two-year period. On March 5, 2015, the Board approved a two-year extension of the stock repurchase program through January 1, 2017. The shares would be purchased from time to time on the open market or in privately negotiated transactions, at the Company's discretion, in each case, in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, subject to market and business conditions, applicable legal requirements, explicit black-out dates and other factors. The purchases will be funded using the Company's available cash balances and cash generated from operations. The program does not obligate the Company to acquire any particular amount of common stock and may be modified, suspended or terminated at any time at the Company's discretion in accordance with Rule 10b-18. During the three months ended December 31, 2015, shares were repurchased as follows:

Period	(a) Total Number of Shares Purchased		(b) Average Price Paid per Share		(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		(d) Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs

October 1 - October 31, 2015		-	$	-		-	$	2,190,824
November 1 - November 30, 2015		50,041		7.68		50,041		1,806,464
December 1 - December 31, 2015		17,981		8.67		17,981		1,650,612
		68,022	$	7.94		68,022		1,650,612

During the three months ended December 31, 2015, Sharps repurchased 68,022 shares for approximately $0.5 million. As of December 31, 2015, approximately $1.7 million remained of our $3.0 million repurchase program.

ITEM 6.

EXHIBITS

(a)	Exhibits:

21.1	Subsidiaries of the Registrant (filed herewith)

31.1	Certification of Chief Executive Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)

31.2	Certification of Chief Financial Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)

32.1	Certification of Chief Executive Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)

32.2	Certification of Chief Financial Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)

101.INS	XBRL Instance Document (filed herewith)

101.SCH	XBRL Taxonomy Extension Schema Document (filed herewith)

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith)

101.DEF	XBRL Taxonomy Extension Linkbase Document (filed herewith)

101.LAB	XBRL Taxonomy Extension Label Linkbase Document (filed herewith)

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith)

ITEMS 3, 4 AND 5 ARE NOT APPLICABLE AND HAVE BEEN OMITTED.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	REGISTRANT:
	SHARPS COMPLIANCE CORP.

Dated: February 4, 2016	By: /s/ DAVID P. TUSA
	David P. Tusa
	Chief Executive Officer and President
	(Principal Executive Officer)

Dated: February 4, 2016	By: /s/ DIANA P. DIAZ
	Diana P. Diaz
	Vice President and Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-21.1 2 ex21_1.htm EXHIBIT 21.1

Exhibit 21.1

Subsidiaries of Registrant

Name	Jurisdiction of Incorporation
Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.)	Texas
Sharps e-Tools.com Inc.	Delaware
Sharps Safety, Inc.	Texas
Sharps Manufacturing, Inc.	Delaware
Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.)	Delaware
Alpha/Bio/Med Services LLC*	Pennsylvania
Bio-Team Mobile LLC**	Pennsylvania

* Added July 17, 2015 as a subsidiary of Sharps Compliance, Inc. of Texas

**Added December 14, 2015 as a subsidiary of Sharps Compliance, Inc. of Texas

EX-31.1 3 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

IN ACCORDANCE WITH SECTION 302 OF THE SARBANES-OXLEY ACT

I, David P. Tusa, certify that:

I have reviewed this quarterly report on Form 10-Q of Sharps Compliance Corp.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: February 4, 2016	/s/David P. Tusa
	Chief Executive Officer and President
	(Principal Executive Officer)

EX-31.2 4 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

IN ACCORDANCE WITH SECTION 302 OF THE SARBANES-OXLEY ACT

I, Diana P. Diaz, certify that:

I have reviewed this quarterly report on Form 10-Q of Sharps Compliance Corp.;

(a)

(b)

(c)

(d)

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: February 4, 2016	/s/Diana P. Diaz
	Vice President and Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 5 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

IN ACCORDANCE WITH SECTION 906 OF THE SARBANES-OXLEY ACT

In connection with the quarterly report of Sharps Compliance Corp. (the “Company”) on Form 10-Q for the period ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof, I, David P. Tusa, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1)

The Form 10-Q report for the period ended December 31, 2015, filed with the Securities and Exchange Commission on February 4, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Form 10-Q report for the period ended December 31, 2015 fairly presents, in all material respects, the financial condition and results of operations of Sharps Compliance Corp.

Date: February 4, 2016	/s/David P. Tusa
	Chief Executive Officer and President

EX-32.2 6 ex32_2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

IN ACCORDANCE WITH SECTION 906 OF THE SARBANES-OXLEY ACT

In connection with the quarterly report of Sharps Compliance Corp. (the “Company”) on Form 10-Q for the period ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof, I, Diana P. Diaz, Vice President and Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1)

(2)

Date: February 4, 2016	/s/Diana P. Diaz
	Vice President and Chief Financial Officer

EX-101.INS 7 smed-20151231.xml XBRL INSTANCE DOCUMENT 0000898770 2015-07-01 2015-12-31 0000898770 2016-02-01 0000898770 2015-06-30 0000898770 2015-12-31 0000898770 2014-10-01 2014-12-31 0000898770 2015-10-01 2015-12-31 0000898770 2014-07-01 2014-12-31 0000898770 us-gaap:TreasuryStockMember 2014-06-30 0000898770 2014-06-30 0000898770 us-gaap:RetainedEarningsMember 2014-06-30 0000898770 us-gaap:CommonStockMember 2014-06-30 0000898770 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0000898770 us-gaap:CommonStockMember 2014-07-01 2015-06-30 0000898770 us-gaap:RetainedEarningsMember 2015-07-01 2015-12-31 0000898770 us-gaap:CommonStockMember 2015-07-01 2015-12-31 0000898770 us-gaap:AdditionalPaidInCapitalMember 2015-07-01 2015-12-31 0000898770 us-gaap:TreasuryStockMember 2015-07-01 2015-12-31 0000898770 us-gaap:TreasuryStockMember 2014-07-01 2015-06-30 0000898770 us-gaap:AdditionalPaidInCapitalMember 2014-07-01 2015-06-30 0000898770 us-gaap:RetainedEarningsMember 2014-07-01 2015-06-30 0000898770 2014-07-01 2015-06-30 0000898770 us-gaap:TreasuryStockMember 2015-12-31 0000898770 us-gaap:TreasuryStockMember 2015-06-30 0000898770 us-gaap:RetainedEarningsMember 2015-12-31 0000898770 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000898770 us-gaap:CommonStockMember 2015-12-31 0000898770 us-gaap:CommonStockMember 2015-06-30 0000898770 us-gaap:AdditionalPaidInCapitalMember 2015-06-30 0000898770 us-gaap:RetainedEarningsMember 2015-06-30 0000898770 2014-12-31 0000898770 smed:AlphaBioMedServicesLLCMember 2015-07-01 2015-12-31 0000898770 smed:BioTeamMobileLLCMember 2015-07-01 2015-12-31 0000898770 smed:CreditAgreementMember 2015-07-01 2015-12-31 0000898770 smed:CreditAgreementMember smed:WorkingCapitalMember 2015-12-31 0000898770 smed:CreditAgreementMember 2015-12-31 0000898770 us-gaap:LetterOfCreditMember smed:CreditAgreementMember 2015-12-31 0000898770 smed:CreditAgreementMember us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2015-12-31 0000898770 smed:CreditAgreementMember us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2015-07-01 2015-12-31 0000898770 smed:CreditAgreementMember smed:WorkingCapitalMember 2015-07-01 2015-12-31 0000898770 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-12-31 0000898770 us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2015-12-31 0000898770 us-gaap:CostOfSalesMember 2015-10-01 2015-12-31 0000898770 us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2014-12-31 0000898770 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-12-31 0000898770 us-gaap:CostOfSalesMember 2014-10-01 2014-12-31 0000898770 us-gaap:CostOfSalesMember 2015-07-01 2015-12-31 0000898770 us-gaap:CostOfSalesMember 2014-07-01 2014-12-31 0000898770 smed:AlphaBioMedServicesLLCMember 2015-07-17 0000898770 smed:BioTeamMobileLLCMember 2015-12-14 0000898770 us-gaap:SubsequentEventMember smed:BioTeamMobileLLCMember 2016-01-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure false --06-30 2015-12-31 No No Yes Smaller Reporting Company SHARPS COMPLIANCE CORP 0000898770 15479286 2016 Q2 10-Q

1723000

1770000

6647000

6306000

2407000

1917000

25013000

24344000

511000

358000

34000

53000

237000

216000

392000

120000

31673000

29751000

25275000

25164000

300000

100000

101000

16000

51000

42000

313000

267000

68000

70000

200000

100000

1033000

700000

15157000

14459000

13717000

16359000

-698000

2642000

158000

156000

15740458

15575041

20000000

0.01

15383791

15481186

-161801

15460940

15575041

15740458

-191250

-259272

6673000

5465000

10178000

11663000

58000

5000

78000

13000

WSJ Prime

P5Y

0.0025

2017-04-09

1877000

2264000

483000

511000

69000

70000

154000

122000

379000

460000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: justify;">NOTE 8 - EARNINGS PER SHARE</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted per share is computed by dividing net income by the weighted average number of common shares after considering the additional dilution related to common stock options, restricted stock and performance-based stock option awards. In computing diluted earnings per share, the outstanding common stock options and performance-based stock option awards are considered dilutive using the treasury stock method.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">The Company’s restricted stock awards are treated as outstanding for earnings per share calculations since these shares have full voting rights and are entitled to participate in dividends declared on common shares, if any, and undistributed earnings.  As participating securities, the shares of restricted stock are included in the calculation of basic EPS using the two-class method.  For the periods presented, the amount of earnings allocated to the participating securities was not material.</div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;"> </div><div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Three-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net income, as reported</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">615</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">749</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">835</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">675</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,467</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,281</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,443</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,285</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Effect of dilutive stock options</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">595</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">142</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">551</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">143</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average diluted common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,062</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,423</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,994</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,428</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net income per common share</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basic</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.05</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.05</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Diluted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.05</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.05</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 9pt; text-indent: -9pt;">Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">120</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">392</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">216</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">237</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div></div>

0.05

0.04

0.05

0.04

0.05

0.04

0.05

0.085

0.019

P2Y7M6D

500000

427000

385000

1039000

413000

626000

3228000

3319000

6198000

5562000

754000

673000

913000

688000

5000

58000

13000

78000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Income Taxes</u></font>:  Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of a valuation allowance requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets.  Under generally accepted accounting principles, the valuation allowance has been recorded to reduce our deferred tax assets to an amount that is more likely than not to be realized and is based on the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes.</div></div>

85000

10000

-434000

-367000

804000

-105000

415000

107000

943000

888000

-111000

445000

-121000

142000

595000

143000

551000

1204000

666000

1345000

2551000

2738000

3787000

1393000

1236000

10000

9000

18000

6394000

5564000

7121000

6165000

31673000

29751000

0.0025

300000

4000000

9000000

500000

5000000

0.035

0.0375

P2Y

8700000

-237000

-1965000

2986000

1494000

675000

835000

749000

615000

835000

1160000

-107000

-227000

9000

10000

18000

744000

664000

895000

670000

118000

216000

128000

540000

1204000

761000

237000

733000

612000

21000

313000

21000

45000

313000

21000

4266000

3810000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Accounts Receivable</u></font>:  Accounts receivable consist primarily of amounts due to the Company from our normal business activities.   Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer.  The Company maintains an allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past collection history and specific risks identified among uncollected accounts.  Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.</div></div>

-105000

730000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Revenue Recognition</u></font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">:  </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company recognizes revenue from product sales and services when goods are shipped or delivered, services provided, and title and risk of loss pass to the customer except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served.  Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse.  During the three and six months ended December 31, 2015, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $1.9 million and $2.5 million, respectively.  During the three and six months ended December 31, 2014, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.8 million and $1.6 million, respectively.  As of December 31, 2015 and June 30, 2015, $2.9 million and $1.6 million, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ and various other solutions like the TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting.  The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price.  The selling price for the transportation revenue and the treatment revenue utilizes third party evidence.  The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities.</div><div> </div><div>Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership.  Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities.  The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities.  Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container.  Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed.  The current and long-term portions of deferred revenues are determined through regression analysis and historical trends.  Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned.  Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.</div></div>

8693000

9992000

17861000

15740000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">The following amounts represent the fair value of the assets acquired and liabilities assumed:  </div><div><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 58%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">51</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 58%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fixed assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">70</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 58%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangibles</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">267</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 58%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">413</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 58%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts payable and accrued liabilities</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(101</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 58%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total purchase price</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">700</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">The following amounts represent the fair value of the assets acquired and liabilities assumed:  </div><div><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 58%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts receivable</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">42</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 58%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fixed assets</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">68</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 58%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangibles</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">313</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 58%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">626</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 58%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts payable and accrued liabilities</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 58%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total purchase price</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,033</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;"> </div><div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Three-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net income, as reported</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">615</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">749</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">835</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">675</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,467</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,281</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,443</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,285</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Effect of dilutive stock options</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">595</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">142</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">551</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">143</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average diluted common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,062</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,423</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,994</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,428</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net income per common share</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basic</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.05</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.05</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Diluted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.05</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.05</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.04</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 9pt; text-indent: -9pt;">Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">120</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">392</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">216</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">237</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>During the three and six months ended December 31, 2015 and 2014, stock-based compensation amounts are as follows (in thousands):</div><div><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Three-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td colspan="4" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 9pt; text-indent: -7.2pt;">Stock-based compensation expense included in:</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Cost of revenues</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">18</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Selling, general and administrative</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">207</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">135</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">340</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">247</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">217</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">141</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">358</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">257</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">The components of inventory are as follows (in thousands):</div><div><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 70%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 46%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">June 30,</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Raw materials</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,236</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,393</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 46%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Finished goods</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,551</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,345</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 46%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,787</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,738</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div></div>

2415000

2585000

5181000

4738000

2.77

2.12

3.98

257000

358000

340000

207000

10000

135000

247000

6000

141000

18000

10000

217000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Stock-Based Compensation</u></font>: Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).</div></div>

3000000

313000

1000

312000

139000

128000

540000

112425

61109

11000

10250

112425

52992

1700000

P2Y

1000

-1000

1000

-1000

29449

68022

29449

68022

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">NOTE 9 - EQUITY TRANSACTIONS</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">During the three and six months ended December 31, 2015 and 2014, stock options to purchase shares of the Company’s common stock were exercised as follows: </div><div><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Three-Months Ended </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six-Months Ended </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options exercised</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">11,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">112,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Proceeds (in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">45</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">21</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">313</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">21</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Average exercise price per share</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3.98</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.77</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">As of December 31, 2015, there was $0.5 million of stock option and restricted stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 2.6 years.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">On January 7, 2013, the Company announced that its Board of Directors approved a stock repurchase program effective January 3, 2013, authorizing the Company to repurchase in the aggregate up to $3.0 million of its outstanding common stock over a two-year period.  On March 5, 2015, the Board approved a two-year extension on the stock repurchase program through January 1, 2017. During the three and six months ended December 31, 2015 and 2014, shares were repurchased as follows: </div><div><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Three-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Shares repurchased</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">68,022</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">68,022</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">29,449</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash paid for shares repurchased (in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">540</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">540</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">128</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Average price paid per share</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.94</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.94</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4.35</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total shares repurchased under the program are 259,272 shares at a cost of $1.3 million.  As of December 31, 2015, approximately $1.7 million remained of the Company’s $3.0 million repurchase program.  Sharps purchased all shares with cash resources.</div></div>

23586000

24552000

-681000

21904000

-1265000

155000

23695000

-1349000

-809000

730000

25013000

158000

156000

24344000

-105000

191250

259272

7.94

4.35

7.94

1349000

809000

15467000

15281000

15285000

15443000

16062000

15423000

15994000

15428000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>During the three and six months ended December 31, 2015 and 2014, shares were repurchased as follows: </div><div><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Three-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six-Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Shares repurchased</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">68,022</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">68,022</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">29,449</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash paid for shares repurchased (in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">540</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">540</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">128</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Average price paid per share</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.94</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.94</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4.35</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">During the three and six months ended December 31, 2015 and 2014, stock options to purchase shares of the Company’s common stock were exercised as follows: </div><div><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Three-Months Ended </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Six-Months Ended </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options exercised</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">11,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">112,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,250</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Proceeds (in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">45</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">21</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">313</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">21</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Average exercise price per share</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3.98</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.77</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr></table></div></div> 1538000 0 529000 0 0 106000 0.8 7000000 0.5 12500000 1.15 0.75 800000 1900000 2500000 1600000 1600000 2900000 P2Y

EX-101.SCH 8 smed-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION AND BACKGROUND link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - RECENTLY ISSUED ACCOUNTING STANDARDS link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - EQUITY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - ACQUISITION link:presentationLink link:calculationLink link:definitionLink 070300 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - EQUITY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 081200 - Disclosure - ACQUISITION (Tables) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - EQUITY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - ACQUISITION (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 smed-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 smed-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 smed-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type SIGNIFICANT ACCOUNTING POLICIES [Abstract] Accounts payable Accounts receivable, net of allowance for doubtful accounts of $53 and $34, respectively Accrued liabilities Additional paid-in capital Additional Paid-in Capital [Member] Adjustments to reconcile net income to net cash provided by operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Accounts receivable, allowance for doubtful accounts Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount ASSETS Assets [Abstract] TOTAL ASSETS Assets TOTAL CURRENT ASSETS Assets, Current CURRENT ASSETS Cash consideration withheld for possible settlement amounts through 2016 Accounts payable and accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Purchase Price Allocation Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Business Acquisition, Acquiree [Domain] Intangibles Business Acquisition [Axis] ACQUISITION [Abstract] Fixed assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets Business Acquisition [Line Items] BASIS OF PRESENTATION ACQUISITION Acquisition related expenses Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Common stock, $0.01 par value per share; 20,000,000 shares authorized; 15,740,458 and 15,575,041 shares issued, respectively and 15,481,186 and 15,383,791 shares outstanding, respectively Common Stock, Value, Issued Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock, par value (in dollars per share) Common Stock [Member] Balances (in shares) Balances (in shares) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Cost of revenues Cost of Revenue Cost of Revenues [Member] Cost of Sales [Member] Credit Facility [Domain] Credit Facility [Axis] INCOME TAX EXPENSE - Current Description of variable rate basis Maturity period Debt Instrument, Term NOTES PAYABLE AND LONG-TERM DEBT [Abstract] Basis spread of variable rate Debt Instrument, Basis Spread on Variable Rate Debt Instrument [Axis] NOTES PAYABLE AND LONG-TERM DEBT Debt Disclosure [Text Block] Maturity date Debt Instrument, Name [Domain] Deferred revenue LONG-TERM DEFERRED REVENUE, net of current portion Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization RECENTLY ISSUED ACCOUNTING STANDARDS STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION [Abstract] Net income per common share Earnings Per Share, Basic [Abstract] EARNINGS PER SHARE Earnings Per Share [Text Block] Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted NET INCOME PER COMMON SHARE EARNINGS PER SHARE [Abstract] Effective income tax rate reconciliation [Abstract] Effective income tax rate Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Weighted average period Compensation expense related to non-vested awards Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Equity Component [Domain] FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract] FAIR VALUE OF FINANCIAL INSTRUMENTS INTANGIBLE ASSETS, accumulated amortization Selling, General and Administrative [Member] General and Administrative Expense [Member] Goodwill GOODWILL GROSS PROFIT Gross Profit Income Statement Location [Axis] CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) [Abstract] INCOME TAXES [Abstract] INCOME BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income Statement Location [Domain] TOTAL INCOME TAX EXPENSE Income Tax Expense (Benefit) INCOME TAXES Income Tax Disclosure [Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Income taxes paid Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable and accrued liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Changes in operating assets and liabilities, net of effects of business acquisition: Inventory Increase (Decrease) in Inventories Restricted cash Increase (Decrease) in Restricted Cash Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Effect of dilutive stock options (in shares) INTANGIBLE ASSETS, net of accumulated amortization of $427 and $385, respectively Intangible Assets, Net (Excluding Goodwill) Finished goods INVENTORY Inventory Disclosure [Text Block] Inventory Total Inventory, Net Raw materials Components of inventory [Abstract] Inventory, Net, Items Net of Reserve Alternative [Abstract] INVENTORY [Abstract] INTEREST INCOME Letters of Credit [Member] TOTAL CURRENT LIABILITIES Liabilities, Current CURRENT LIABILITIES TOTAL LIABILITIES Liabilities LIABILITIES AND STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Line of Credit Facility [Table] Unused capacity, commitment fee percentage Amount outstanding Maximum borrowing capacity Interest rate Line of Credit Facility [Line Items] Period of line of credit Remaining borrowing capacity ORGANIZATION AND BACKGROUND Nature of Operations [Text Block] CASH FLOWS FROM FINANCING ACTIVITIES CASH FLOWS FROM OPERATING ACTIVITIES NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities, Continuing Operations NET CASH PROVIDED BY OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net income Net income NET INCOME Net income, as reported CASH FLOWS FROM INVESTING ACTIVITIES NET CASH USED IN FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities, Continuing Operations RECENTLY ISSUED ACCOUNTING STANDARDS [Abstract] NON-CASH INVESTING ACTIVITIES: TOTAL INTEREST INCOME Nonoperating Income (Expense) OPERATING INCOME Operating Income (Loss) ORGANIZATION AND BACKGROUND [Abstract] OTHER LONG-TERM LIABILITIES Shares repurchased Cash paid for shares repurchased Payments for acquisition, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Purchase of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Prepaid and other current assets Prepaid Expense and Other Assets, Current Proceeds from exercise of stock options Proceeds Proceeds from Stock Options Exercised PROPERTY, PLANT AND EQUIPMENT, net Accounts Receivable Retained Earnings (Accumulated Deficit) [Member] Retained earnings (accumulated deficit) Revenue Recognition [Abstract] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] REVENUES Revenue, Net Preliminary purchase price allocation Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Earnings per share Allocated cost of share based compensation EX-101.PRE 12 smed-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Dec. 31, 2015	Feb. 01, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	SHARPS COMPLIANCE CORP
Entity Central Index Key	0000898770
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		15,479,286
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2015

XML 14 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Dec. 31, 2015	Jun. 30, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 14,459	$ 15,157
Accounts receivable, net of allowance for doubtful accounts of $53 and $34, respectively	6,306	6,647
Inventory	3,787	2,738
Prepaid and other current assets	612	733
TOTAL CURRENT ASSETS	25,164	25,275
PROPERTY, PLANT AND EQUIPMENT, net	4,266	3,810
GOODWILL	1,039	0
INTANGIBLE ASSETS, net of accumulated amortization of $427 and $385, respectively	1,204	666
TOTAL ASSETS	31,673	29,751
CURRENT LIABILITIES
Accounts payable	1,723	1,770
Accrued liabilities	2,407	1,917
Deferred revenue	2,264	1,877
TOTAL CURRENT LIABILITIES	6,394	5,564
LONG-TERM DEFERRED REVENUE, net of current portion	511	483
OTHER LONG-TERM LIABILITIES	216	118
TOTAL LIABILITIES	$ 7,121	$ 6,165
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common stock, $0.01 par value per share; 20,000,000 shares authorized; 15,740,458 and 15,575,041 shares issued, respectively and 15,481,186 and 15,383,791 shares outstanding, respectively	$ 158	$ 156
Treasury stock, at cost, 259,272 and 191,250 shares repurchased, respectively	(1,349)	(809)
Additional paid-in capital	25,013	24,344
Retained earnings (accumulated deficit)	730	(105)
TOTAL STOCKHOLDERS' EQUITY	24,552	23,586
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 31,673	$ 29,751

XML 15 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Jun. 30, 2015
CURRENT ASSETS
Accounts receivable, allowance for doubtful accounts	$ 53	$ 34
INTANGIBLE ASSETS, accumulated amortization	$ 427	$ 385
STOCKHOLDERS' EQUITY
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	15,740,458	15,575,041
Common stock, shares outstanding (in shares)	15,481,186	15,383,791
Treasury stock, shares repurchased (in shares)	259,272	191,250

XML 16 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) [Abstract]
REVENUES	$ 9,992	$ 8,693	$ 17,861	$ 15,740
Cost of revenues	6,673	5,465	11,663	10,178
GROSS PROFIT	3,319	3,228	6,198	5,562
Selling, general and administrative	2,585	2,415	5,181	4,738
Depreciation and amortization	70	69	122	154
OPERATING INCOME	664	744	895	670
INTEREST INCOME	9	10	18	18
TOTAL INTEREST INCOME	9	10	18	18
INCOME BEFORE INCOME TAXES	673	754	913	688
INCOME TAX EXPENSE - Current	58	5	78	13
TOTAL INCOME TAX EXPENSE	58	5	78	13
NET INCOME	$ 615	$ 749	$ 835	$ 675
NET INCOME PER COMMON SHARE
Basic (in dollars per share)	$ 0.04	$ 0.05	$ 0.05	$ 0.04
Diluted (in dollars per share)	$ 0.04	$ 0.05	$ 0.05	$ 0.04
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME PER COMMON SHARE:
Basic (in shares)	15,467	15,281	15,443	15,285
Diluted (in shares)	16,062	15,423	15,994	15,428

XML 17 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]	Total
Balances at Jun. 30, 2014	$ 155	$ (681)	$ 23,695	$ (1,265)	$ 21,904
Balances (in shares) at Jun. 30, 2014	15,460,940	(161,801)
Exercise of stock options	$ 0	$ 0	139	0	139
Exercise of stock options (in shares)	61,109	0
Stock-based compensation	$ 0	$ 0	511	0	511
Issuance of restricted stock	$ 1	$ 0	(1)	0	0
Issuance of restricted stock (in shares)	52,992	0
Shares repurchased	$ 0	$ (128)	0	0	(128)
Shares repurchased (in shares)	0	(29,449)
Net income	$ 0	$ 0	0	1,160	1,160
Balances at Jun. 30, 2015	$ 156	$ (809)	24,344	(105)	$ 23,586
Balances (in shares) at Jun. 30, 2015	15,575,041	(191,250)			15,383,791
Exercise of stock options	$ 1	$ 0	312	0	$ 313
Exercise of stock options (in shares)	112,425	0			112,425
Stock-based compensation	$ 0	$ 0	358	0	$ 358
Issuance of restricted stock	$ 1	0	(1)	0	0
Issuance of restricted stock (in shares)	52,992
Shares repurchased	$ 0	$ (540)	0	0	$ (540)
Shares repurchased (in shares)	0	(68,022)			(68,022)
Net income	$ 0	$ 0	0	835	$ 835
Balances at Dec. 31, 2015	$ 158	$ (1,349)	$ 25,013	$ 730	$ 24,552
Balances (in shares) at Dec. 31, 2015	15,740,458	(259,272)			15,481,186

XML 18 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 835	$ 675
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	379	460
Stock-based compensation expense	358	257
Changes in operating assets and liabilities, net of effects of business acquisition:
Restricted cash	0	111
Accounts receivable	434	367
Legal settlement receivable	0	1,538
Inventory	(943)	(888)
Prepaid and other current assets	121	(445)
Accounts payable and accrued liabilities	(105)	804
Deferred revenue	415	107
NET CASH PROVIDED BY OPERATING ACTIVITIES	1,494	2,986
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(761)	(237)
Payments for acquisition, net of cash acquired	(1,204)	0
NET CASH USED IN INVESTING ACTIVITIES	(1,965)	(237)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of stock options	313	21
Shares repurchased	(540)	(128)
NET CASH USED IN FINANCING ACTIVITIES	(227)	(107)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(698)	2,642
CASH AND CASH EQUIVALENTS, beginning of period	15,157	13,717
CASH AND CASH EQUIVALENTS, end of period	14,459	16,359
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Income taxes paid	85	10
NON-CASH INVESTING ACTIVITIES:
Unpaid consideration related to acquisition	529	0
Transfer of equipment to inventory	$ 106	$ 0

XML 19 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND BACKGROUND	6 Months Ended
ORGANIZATION AND BACKGROUND	Dec. 31, 2015
ORGANIZATION AND BACKGROUND [Abstract]
ORGANIZATION AND BACKGROUND	NOTE 1 - ORGANIZATION AND BACKGROUND The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com, Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.), Sharps Safety, Inc., Alpha Bio/Med Services LLC and Bio-Team Mobile LLC (collectively, “Sharps” or the “Company”). All significant intercompany accounts and transactions have been eliminated upon consolidation.

XML 20 R8.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION	6 Months Ended
BASIS OF PRESENTATION	Dec. 31, 2015
BASIS OF PRESENTATION [Abstract]
BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of December 31, 2015, the results of its operations for the three and six months ended December 31, 2015 and 2014, cash flows for the six months ended December 31, 2015 and 2014 and stockholders’ equity for the six months ended December 31, 2015 and the year ended June 30, 2015. The results of operations for the three and six months ended December 31, 2015 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2016. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended June 30, 2015.

XML 21 R9.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
SIGNIFICANT ACCOUNTING POLICIES	Dec. 31, 2015
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition: The Company recognizes revenue from product sales and services when goods are shipped or delivered, services provided, and title and risk of loss pass to the customer except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse. During the three and six months ended December 31, 2015, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $1.9 million and $2.5 million, respectively. During the three and six months ended December 31, 2014, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.8 million and $1.6 million, respectively. As of December 31, 2015 and June 30, 2015, $2.9 million and $1.6 million, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program. Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ and various other solutions like the TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service. In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting. The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price. The selling price for the transportation revenue and the treatment revenue utilizes third party evidence. The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities. Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container. Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned. Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale. Income Taxes: Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of a valuation allowance requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under generally accepted accounting principles, the valuation allowance has been recorded to reduce our deferred tax assets to an amount that is more likely than not to be realized and is based on the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes. Accounts Receivable: Accounts receivable consist primarily of amounts due to the Company from our normal business activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer. The Company maintains an allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past collection history and specific risks identified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts. Stock-Based Compensation: Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).

XML 22 R10.htm IDEA: XBRL DOCUMENT

RECENTLY ISSUED ACCOUNTING STANDARDS	6 Months Ended
RECENTLY ISSUED ACCOUNTING STANDARDS	Dec. 31, 2015
RECENTLY ISSUED ACCOUNTING STANDARDS [Abstract]
RECENTLY ISSUED ACCOUNTING STANDARDS	NOTE 4 – RECENTLY ISSUED ACCOUNTING STANDARDS In May 2014, guidance for revenue recognition was issued which supersedes the revenue recognition requirements currently followed by the Company. The new guidance provides for a single five-step model to be applied in determining the amount and timing of the recognition of revenue related to contracts with customers. The new standard also requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. The guidance is effective for annual reporting periods beginning after December 15, 2017 (effective July 1, 2018 for the Company). The Company is evaluating the impact that the new accounting guidance will have on its consolidated financial statements and related disclosures and has not yet determined the method by which it will adopt the standard. In July 2015, guidance for inventory measurement was issued, which supersedes the policy currently followed by the Company. The new guidance requires the Company to measure inventory at the lower of cost or net realizable value. The provisions of the new guidance are effective for annual reporting periods beginning after December 15, 2016 (effective July 1, 2017 for the Company) including interim periods within the reporting period. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements. In September 2015, guidance for business combinations was issued, which simplifies the accounting for measurement-period adjustments. The new guidance eliminates the requirement to restate prior period financial statements for measurement period adjustments following a business combination and requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. The provisions of the new guidance are effective for annual reporting periods beginning after December 15, 2015 (effective July 1, 2016 for the Company) including interim periods within the reporting period. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

XML 23 R11.htm IDEA: XBRL DOCUMENT

INCOME TAXES	6 Months Ended
INCOME TAXES	Dec. 31, 2015
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 5 - INCOME TAXES The establishment of valuation allowances and development of projected annual effective tax rates requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under generally accepted accounting principles, the valuation allowance has been recorded to reduce the Company’s net deferred tax asset to an amount that is more likely than not to be realized and is based upon the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes. The Company’s net deferred tax assets have been fully reserved by a tax valuation allowance. The Company’s effective tax rate for the six months ended December 31, 2015 and 2014 was 8.5% and 1.9%, respectively, reflecting estimated state income taxes. The Company’s federal tax expense associated with taxable income during the six months ended December 31, 2015 and 2014 was offset by the utilization of net operating loss carryforwards.

XML 24 R12.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LONG-TERM DEBT	6 Months Ended
NOTES PAYABLE AND LONG-TERM DEBT	Dec. 31, 2015
NOTES PAYABLE AND LONG-TERM DEBT [Abstract]
NOTES PAYABLE AND LONG-TERM DEBT	NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT On April 9, 2015, the Company entered into a credit agreement with a commercial bank (“Credit Agreement”). The Credit Agreement, which replaces, in its entirety, the Company’s prior credit agreement, which was executed effective January 28, 2014 with the same commercial bank, provides for a two-year, $9.0 million line of credit facility, the proceeds of which may be utilized as follows: (i) $4.0 million for working capital, letters of credit (up to $500,000) and general corporate purposes and (ii) $5.0 million for acquisitions. Indebtedness under the Credit Agreement is secured by the Company’s accounts receivable and inventory with advances outstanding under the working capital portion of the credit facility at any time limited to a Borrowing Base (as defined in the Credit Agreement) equal to 80% of eligible accounts receivable plus 50% of eligible inventory. Advances under the acquisition portion of the credit facility are limited to 75% of the purchase price of an acquired company and convert to a five-year term note. Borrowings bear interest at WSJ Prime (for the working capital line) and WSJ Prime plus 0.25% (for the acquisition line), which was approximately 3.50% and 3.75%, respectively, as of December 31, 2015. The Company pays a fee of 0.25% per annum on the unused amount of the line of credit. As of December 31, 2015, the Company had no outstanding borrowings other than $0.3 million in letters of credit, which left $8.7 million of credit available under the Credit Agreement. The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a minimum level of tangible net worth of $12.5 million, minimum liquidity of $7.0 million and a minimum debt service coverage ratio of not less than 1.15 to 1.00. The Credit Agreement, which expires on April 9, 2017, also contains customary events of default which, if uncured, may terminate the Credit Agreement and require immediate repayment of all indebtedness to the lenders. The Company was in compliance with all the financial covenants under the Credit Agreement as of December 31, 2015.

XML 25 R13.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

6 Months Ended

Dec. 31, 2015

STOCK-BASED COMPENSATION [Abstract]

STOCK-BASED COMPENSATION

NOTE 7 – STOCK-BASED COMPENSATION

	Three-Months Ended				Six-Months Ended
	December 31,				December 31,
	2015		2014		2015		2014
	(Unaudited)				(Unaudited)
Stock-based compensation expense included in:

Cost of revenues	$	10	$	6	$	18	$	10
Selling, general and administrative		207		135		340		247
Total	$	217	$	141	$	358	$	257

XML 26 R14.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE

6 Months Ended

Dec. 31, 2015

EARNINGS PER SHARE [Abstract]

EARNINGS PER SHARE

NOTE 8 - EARNINGS PER SHARE

The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):

	Three-Months Ended				Six-Months Ended
	December 31,				December 31,
	2015		2014		2015		2014
	(Unaudited)				(Unaudited)
Net income, as reported	$	615	$	749	$	835	$	675

Weighted average common shares outstanding		15,467		15,281		15,443		15,285
Effect of dilutive stock options		595		142		551		143
Weighted average diluted common shares outstanding		16,062		15,423		15,994		15,428

Net income per common share
Basic	$	0.04	$	0.05	$	0.05	$	0.04
Diluted	$	0.04	$	0.05	$	0.05	$	0.04

Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive		120		392		216		237

XML 27 R15.htm IDEA: XBRL DOCUMENT

EQUITY TRANSACTIONS

6 Months Ended

Dec. 31, 2015

EQUITY TRANSACTIONS [Abstract]

EQUITY TRANSACTIONS

NOTE 9 - EQUITY TRANSACTIONS

During the three and six months ended December 31, 2015 and 2014, stock options to purchase shares of the Company’s common stock were exercised as follows:

	Three-Months Ended December 31,				Six-Months Ended December 31,
	2015		2014		2015		2014
	(Unaudited)				(Unaudited)
Options exercised		11,000		10,250		112,425		10,250
Proceeds (in thousands)	$	45	$	21	$	313	$	21
Average exercise price per share	$	3.98	$	2.12	$	2.77	$	2.12

	Three-Months Ended						Six-Months Ended
	December 31,						December 31,
	2015			2014			2015			2014
	(Unaudited)						(Unaudited)
Shares repurchased			68,022			-			68,022			29,449
Cash paid for shares repurchased (in thousands)		$	540		$	-		$	540		$	128
Average price paid per share		$	7.94		$	-		$	7.94		$	4.35

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 28 R16.htm IDEA: XBRL DOCUMENT

INVENTORY

6 Months Ended

Dec. 31, 2015

INVENTORY [Abstract]

INVENTORY

NOTE 10 – INVENTORY

The components of inventory are as follows (in thousands):

	December 31, 2015		June 30, 2015
	(Unaudited)
Raw materials	$	1,236	$	1,393
Finished goods		2,551		1,345
Total	$	3,787	$	2,738

XML 29 R17.htm IDEA: XBRL DOCUMENT

FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
FAIR VALUE OF FINANCIAL INSTRUMENTS	Dec. 31, 2015
FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	NOTE 11 – FAIR VALUE OF FINANCIAL INSTRUMENTS The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable and accounts payable to approximate their carrying values at December 31, 2015 due to their short-term nature.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 30 R18.htm IDEA: XBRL DOCUMENT

ACQUISITION

6 Months Ended

Dec. 31, 2015

ACQUISITION [Abstract]

ACQUISITION

NOTE 12 – ACQUISITIONS

The following amounts represent the fair value of the assets acquired and liabilities assumed:

Accounts receivable	$	51
Fixed assets		70
Intangibles		267
Goodwill		413
Accounts payable and accrued liabilities		(101	)
Total purchase price	$	700

The following amounts represent the fair value of the assets acquired and liabilities assumed:

Accounts receivable	$	42
Fixed assets		68
Intangibles		313
Goodwill		626
Accounts payable and accrued liabilities		(16	)
Total purchase price	$	1,033

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 31 R19.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Dec. 31, 2015
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Revenue Recognition	Revenue Recognition: The Company recognizes revenue from product sales and services when goods are shipped or delivered, services provided, and title and risk of loss pass to the customer except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse. During the three and six months ended December 31, 2015, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $1.9 million and $2.5 million, respectively. During the three and six months ended December 31, 2014, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.8 million and $1.6 million, respectively. As of December 31, 2015 and June 30, 2015, $2.9 million and $1.6 million, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program. Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ and various other solutions like the TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service. In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting. The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price. The selling price for the transportation revenue and the treatment revenue utilizes third party evidence. The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities. Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container. Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned. Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.
Income Taxes	Income Taxes: Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of a valuation allowance requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under generally accepted accounting principles, the valuation allowance has been recorded to reduce our deferred tax assets to an amount that is more likely than not to be realized and is based on the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes.
Accounts Receivable	Accounts Receivable: Accounts receivable consist primarily of amounts due to the Company from our normal business activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer. The Company maintains an allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past collection history and specific risks identified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.
Stock-Based Compensation	Stock-Based Compensation: Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

XML 32 R20.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Dec. 31, 2015

STOCK-BASED COMPENSATION [Abstract]

Allocated cost of share based compensation

During the three and six months ended December 31, 2015 and 2014, stock-based compensation amounts are as follows (in thousands):

	Three-Months Ended				Six-Months Ended
	December 31,				December 31,
	2015		2014		2015		2014
	(Unaudited)				(Unaudited)
Stock-based compensation expense included in:

Cost of revenues	$	10	$	6	$	18	$	10
Selling, general and administrative		207		135		340		247
Total	$	217	$	141	$	358	$	257

XML 33 R21.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

6 Months Ended

Dec. 31, 2015

EARNINGS PER SHARE [Abstract]

Earnings per share

The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):

	Three-Months Ended				Six-Months Ended
	December 31,				December 31,
	2015		2014		2015		2014
	(Unaudited)				(Unaudited)
Net income, as reported	$	615	$	749	$	835	$	675

Weighted average common shares outstanding		15,467		15,281		15,443		15,285
Effect of dilutive stock options		595		142		551		143
Weighted average diluted common shares outstanding		16,062		15,423		15,994		15,428

Net income per common share
Basic	$	0.04	$	0.05	$	0.05	$	0.04
Diluted	$	0.04	$	0.05	$	0.05	$	0.04

Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive		120		392		216		237

XML 34 R22.htm IDEA: XBRL DOCUMENT

EQUITY TRANSACTIONS (Tables)

6 Months Ended

Dec. 31, 2015

EQUITY TRANSACTIONS [Abstract]

Stock options exercised to purchase common stock

During the three and six months ended December 31, 2015 and 2014, stock options to purchase shares of the Company’s common stock were exercised as follows:

	Three-Months Ended December 31,				Six-Months Ended December 31,
	2015		2014		2015		2014
	(Unaudited)				(Unaudited)
Options exercised		11,000		10,250		112,425		10,250
Proceeds (in thousands)	$	45	$	21	$	313	$	21
Average exercise price per share	$	3.98	$	2.12	$	2.77	$	2.12

Schedule of share repurchases

During the three and six months ended December 31, 2015 and 2014, shares were repurchased as follows:

	Three-Months Ended						Six-Months Ended
	December 31,						December 31,
	2015			2014			2015			2014
	(Unaudited)						(Unaudited)
Shares repurchased			68,022			-			68,022			29,449
Cash paid for shares repurchased (in thousands)		$	540		$	-		$	540		$	128
Average price paid per share		$	7.94		$	-		$	7.94		$	4.35

XML 35 R23.htm IDEA: XBRL DOCUMENT

INVENTORY (Tables)

6 Months Ended

Dec. 31, 2015

INVENTORY [Abstract]

Components of inventory

The components of inventory are as follows (in thousands):

	December 31, 2015		June 30, 2015
	(Unaudited)
Raw materials	$	1,236	$	1,393
Finished goods		2,551		1,345
Total	$	3,787	$	2,738

XML 36 R24.htm IDEA: XBRL DOCUMENT

ACQUISITION (Tables)

6 Months Ended

Dec. 31, 2015

Alpha Bio Med Services LLC [Member]

Business Acquisition [Line Items]

Preliminary purchase price allocation

The following amounts represent the fair value of the assets acquired and liabilities assumed:

Accounts receivable	$	51
Fixed assets		70
Intangibles		267
Goodwill		413
Accounts payable and accrued liabilities		(101	)
Total purchase price	$	700

Bio-Team Mobile LLC [Member]

Business Acquisition [Line Items]

Preliminary purchase price allocation

The following amounts represent the fair value of the assets acquired and liabilities assumed:

Accounts receivable	$	42
Fixed assets		68
Intangibles		313
Goodwill		626
Accounts payable and accrued liabilities		(16	)
Total purchase price	$	1,033

XML 37 R25.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015
Revenue Recognition [Abstract]
Revenue recorded from bill and hold inventory	$ 1.9	$ 0.8	$ 2.5	$ 1.6
Bill and hold inventory	$ 2.9		$ 2.9		$ 1.6

XML 38 R26.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details)	6 Months Ended
INCOME TAXES (Details)	Dec. 31, 2015	Dec. 31, 2014
Effective income tax rate reconciliation [Abstract]
Effective income tax rate	8.50%	1.90%

XML 39 R27.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LONG-TERM DEBT (Details) - Credit Agreement [Member]	6 Months Ended
	Dec. 31, 2015 USD ($)
Line of Credit Facility [Line Items]
Period of line of credit	2 years
Maximum borrowing capacity	$ 9,000,000
Percentage of eligible accounts receivable considered for borrowing base	80.00%
Percentage of eligible inventory considered for borrowing base	50.00%
Percentage of portion allocated to acquisition purchase price	75.00%
Maturity period	5 years
Unused capacity, commitment fee percentage	0.25%
Amount outstanding	$ 0
Remaining borrowing capacity	8,700,000
Minimum amount of tangible net worth to be maintained under financial covenants	12,500,000
Minimum amount of liquidity to be maintained under financial covenants	$ 7,000,000
Minimum debt service coverage ratio	1.15
Maturity date	Apr. 09, 2017
Working Capital [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 4,000,000
Description of variable rate basis	WSJ Prime
Interest rate	3.50%
Letters of Credit [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 500,000
Amount outstanding	300,000
Acquisitions [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 5,000,000
Description of variable rate basis	WSJ Prime
Interest rate	3.75%
Basis spread of variable rate	0.25%

XML 40 R28.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 217	$ 141	$ 358	$ 257
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	10	6	18	10
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 207	$ 135	$ 340	$ 247

XML 41 R29.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015
EARNINGS PER SHARE [Abstract]
Net income, as reported	$ 615	$ 749	$ 835	$ 675	$ 1,160
Weighted average common shares outstanding (in shares)	15,467	15,281	15,443	15,285
Effect of dilutive stock options (in shares)	595	142	551	143
Weighted average diluted common shares outstanding (in shares)	16,062	15,423	15,994	15,428
Net income per common share
Basic (in dollars per share)	$ 0.04	$ 0.05	$ 0.05	$ 0.04
Diluted (in dollars per share)	$ 0.04	$ 0.05	$ 0.05	$ 0.04
Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive (in shares)	120	392	216	237

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 42 R30.htm IDEA: XBRL DOCUMENT

EQUITY TRANSACTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015
Stock options exercised [Abstract]
Options Exercised (in shares)	11,000	10,250	112,425	10,250
Proceeds	$ 45	$ 21	$ 313	$ 21
Average exercise price per share (in dollars per share)	$ 3.98	$ 2.12	$ 2.77	$ 2.12
Compensation expense related to non-vested awards	$ 500		$ 500
Weighted average period			2 years 7 months 6 days
Stock repurchase program, authorized amount	$ 3,000		$ 3,000
Stock repurchase program, period			2 years
Stock repurchase program term extension			2 years
Shares repurchased [Abstract]
Shares repurchased (in shares)	68,022	0	68,022	29,449
Cash paid for shares repurchased	$ 540	$ 0	$ 540	$ 128
Average price paid per share (in dollars per share)	$ 7.94	$ 0	$ 7.94	$ 4.35
Total shares repurchased under the program (in shares)	259,272		259,272		191,250
Total shares repurchased under the program, at cost	$ 1,349		$ 1,349		$ 809
Amount remaining under repurchase program	$ 1,700		$ 1,700

XML 43 R31.htm IDEA: XBRL DOCUMENT

INVENTORY (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Jun. 30, 2015
Components of inventory [Abstract]
Raw materials	$ 1,236	$ 1,393
Finished goods	2,551	1,345
Total	$ 3,787	$ 2,738

XML 44 R32.htm IDEA: XBRL DOCUMENT

ACQUISITION (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
ACQUISITION (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2015	Jan. 31, 2016	Dec. 14, 2015	Jul. 17, 2015	Jun. 30, 2015
Purchase Price Allocation
Goodwill	$ 1,039	$ 1,039				$ 0
Acquisition related expenses	$ 100	$ 200
Alpha Bio Med Services LLC [Member]
Purchase Price Allocation
Accounts receivable					$ 51
Fixed assets					70
Intangibles					267
Goodwill					413
Accounts payable and accrued liabilities					(101)
Total purchase price					700
Cash consideration withheld for possible settlement amounts through 2016					$ 100
Bio-Team Mobile LLC [Member]
Purchase Price Allocation
Accounts receivable				$ 42
Fixed assets				68
Intangibles				313
Goodwill				626
Accounts payable and accrued liabilities				(16)
Total purchase price				1,033
Cash consideration withheld for possible settlement amounts through 2016				$ 100
Bio-Team Mobile LLC [Member] \| Subsequent Event [Member]
Purchase Price Allocation
Cash consideration withheld for possible settlement amounts through 2016			$ 300

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 50 147 1 false 13 0 false 4 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://sharpsinc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://sharpsinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://sharpsinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Sheet http://sharpsinc.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Statements 4 false false R5.htm 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://sharpsinc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://sharpsinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 060100 - Disclosure - ORGANIZATION AND BACKGROUND Sheet http://sharpsinc.com/role/OrganizationAndBackground ORGANIZATION AND BACKGROUND Notes 7 false false R8.htm 060200 - Disclosure - BASIS OF PRESENTATION Sheet http://sharpsinc.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 060300 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://sharpsinc.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 060400 - Disclosure - RECENTLY ISSUED ACCOUNTING STANDARDS Sheet http://sharpsinc.com/role/RecentlyIssuedAccountingStandards RECENTLY ISSUED ACCOUNTING STANDARDS Notes 10 false false R11.htm 060500 - Disclosure - INCOME TAXES Sheet http://sharpsinc.com/role/IncomeTaxes INCOME TAXES Notes 11 false false R12.htm 060600 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT Notes http://sharpsinc.com/role/NotesPayableAndLongtermDebt NOTES PAYABLE AND LONG-TERM DEBT Notes 12 false false R13.htm 060700 - Disclosure - STOCK-BASED COMPENSATION Sheet http://sharpsinc.com/role/StockbasedCompensation STOCK-BASED COMPENSATION Notes 13 false false R14.htm 060800 - Disclosure - EARNINGS PER SHARE Sheet http://sharpsinc.com/role/EarningsPerShare EARNINGS PER SHARE Notes 14 false false R15.htm 060900 - Disclosure - EQUITY TRANSACTIONS Sheet http://sharpsinc.com/role/EquityTransactions EQUITY TRANSACTIONS Notes 15 false false R16.htm 061000 - Disclosure - INVENTORY Sheet http://sharpsinc.com/role/Inventory INVENTORY Notes 16 false false R17.htm 061100 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://sharpsinc.com/role/FairValueOfFinancialInstruments FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 17 false false R18.htm 061200 - Disclosure - ACQUISITION Sheet http://sharpsinc.com/role/Acquisition ACQUISITION Notes 18 false false R19.htm 070300 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://sharpsinc.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 080700 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://sharpsinc.com/role/StockbasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://sharpsinc.com/role/StockbasedCompensation 20 false false R21.htm 080800 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://sharpsinc.com/role/EarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://sharpsinc.com/role/EarningsPerShare 21 false false R22.htm 080900 - Disclosure - EQUITY TRANSACTIONS (Tables) Sheet http://sharpsinc.com/role/EquityTransactionsTables EQUITY TRANSACTIONS (Tables) Tables http://sharpsinc.com/role/EquityTransactions 22 false false R23.htm 081000 - Disclosure - INVENTORY (Tables) Sheet http://sharpsinc.com/role/InventoryTables INVENTORY (Tables) Tables http://sharpsinc.com/role/Inventory 23 false false R24.htm 081200 - Disclosure - ACQUISITION (Tables) Sheet http://sharpsinc.com/role/AcquisitionTables ACQUISITION (Tables) Tables http://sharpsinc.com/role/Acquisition 24 false false R25.htm 090300 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://sharpsinc.com/role/SignificantAccountingPoliciesDetails SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://sharpsinc.com/role/SignificantAccountingPoliciesPolicies 25 false false R26.htm 090500 - Disclosure - INCOME TAXES (Details) Sheet http://sharpsinc.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://sharpsinc.com/role/IncomeTaxes 26 false false R27.htm 090600 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT (Details) Notes http://sharpsinc.com/role/NotesPayableAndLongtermDebtDetails NOTES PAYABLE AND LONG-TERM DEBT (Details) Details http://sharpsinc.com/role/NotesPayableAndLongtermDebt 27 false false R28.htm 090700 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://sharpsinc.com/role/StockbasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://sharpsinc.com/role/StockbasedCompensationTables 28 false false R29.htm 090800 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://sharpsinc.com/role/EarningsPerShareDetails EARNINGS PER SHARE (Details) Details http://sharpsinc.com/role/EarningsPerShareTables 29 false false R30.htm 090900 - Disclosure - EQUITY TRANSACTIONS (Details) Sheet http://sharpsinc.com/role/EquityTransactionsDetails EQUITY TRANSACTIONS (Details) Details http://sharpsinc.com/role/EquityTransactionsTables 30 false false R31.htm 091000 - Disclosure - INVENTORY (Details) Sheet http://sharpsinc.com/role/InventoryDetails INVENTORY (Details) Details http://sharpsinc.com/role/InventoryTables 31 false false R32.htm 091200 - Disclosure - ACQUISITION (Details) Sheet http://sharpsinc.com/role/AcquisitionDetails ACQUISITION (Details) Details http://sharpsinc.com/role/AcquisitionTables 32 false false All Reports Book All Reports smed-20151231.xml smed-20151231.xsd smed-20151231_cal.xml smed-20151231_def.xml smed-20151231_lab.xml smed-20151231_pre.xml true true ZIP 51 0001140361-16-050280-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-16-050280-xbrl.zip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
>T%M(NIX1QPS':P=?J7XV43]$_UZ"0OTFVZ MMJU[/IMR3_"PB(4KW;OT*->>2984U1!:A95.FI7SBR]O?FX=M8I!-*^;73*4 MQU8%#$D7*1398)=AX ,\[/UC[,-+X9BA:6W\R7>.GV>Y53 M5&HU0&MI@]F9Y,9)*K/K)(U0?-:G1'@PKZV07Y)4-:,^G)HF47OSLDO:7^= MEY"?RK2,1OF@>V+7R*LKMIFR M?Q-D?]$-*E$HZGX2O9>C-+4)L07[4;XL))HE3$0YU'PL%#G,_?SWFS^S*\^: M\$039;C:C%[^[GIXB(.=ZE,+#Z+M2MZ2#DG&#F5Y%[#DK0:[Y=YD@?@62@G? M72J+U7F\ZOTZCSOL:3X/0BDW4\K@#B")V&?(_\YLEJ@21%TZ:8UH];37C$OM MIEUJE]:!6NW>//7,9S6KM.3<#?L'GKQA=/2F4(ZO,2M]OI1,'P90_'##KH:_ M#C]]/6/#B\_LZ^7%+\W;L^MO[//9I]O:G/'+D'_IL.'4LVQV4G1^CU(=T*&S MP&4Z,X2)ZK&)4MT%':N=3+A')1OP,%ZF\LNL6:?+P(C*%K-/-.1Q/8]/;=U M)BR'ZG^(DA/!%?-Y:V%EOIK/4@4'_"+TP M6#XWR>.*XCE!@1X9.'L?"\O@B<;GN3K3\^D03;5J#'DR(/IWD MY.4LF^^PY OT"*\?MW[$#CG8&9V"+&)M:H<^Z\T\&/-ZQ(81GPEOZ<.PR_CR M,OP,>C]&3V9/]M,I4")K&TCMI FF]Z)VW(^A2,Z,G" MD15B@<7)7^1_(^U9]]Y)B3= 0MN)6C.TXX8:[0?NB$ M>.A6I*J)9)NU==#AHJ)&47=C'4^M9^!\E\C5Q?J,F-#'R2;^ 1#F##T2"Q[> M9C\<9VMZ1,[P0;=L N!\@ZU/AJ!A-MP^+WXPW#! MIG214TD'&8'*L.:5E"L*N1&5 ,OH!6 _@99%]2R&!\$GH'Z; Y)(W_+&.W04 M(++!-5$NJ/91+SG/'K]E0?LF&B8^,TAY53IF'C^'_C3.1X6$>_H]39PL5U3I M"H WQ=XT(ZT'E*I0:RW> 3E3U/+$^?6TX/\ (1A^VXB0P/$#3H!5XNK3.+L M.'@]/;0#T1(,P2, #OGR!HU5Z WP>"(O=OVB:IP0K@7CIVGAHUAP[IE^1_=# MQ=E2(PFP1,:$-PL\/VN;:/%4\VDRM:VD3!VV03FBXI)1B=87#$SSW,'R0^IS M0MXX?/ZF!U@6[YF.VK]TOA8U\AEEMKEY&VJ^V>HV6R?SY@?ICE,S@A&G.QQ> M\>IG]+M2JY3MV;M?U:,E5RIZG=7HLI$<*DGEI$>LS_9GGH#.9;T+PNM\A, M.91U^_--9RDSUV>G9Q>W7W]EYS.$&O_)@:+K3H/#LXV&M[LW4G.QF2DZN(N9Z MSJ+.'?9-?Y;U;^]A5D)1-$ZU9?!$]SSO'3'=IGA;G-,54PD_A*DPS'RY+XO# MYM^1\;ZL/RS&8OM9+F/EUH!$?.\ (S$Q,PMK/A9UYF(%P@_XE$U)*6-B3&2BANSDK!X)#6!6RMT MSQBFEJ[8O4-:?,ZX19-E'1H*/#=:3Q$K+SI@ I=:PPE5!L=;TK2@FBH@G3P( M[5E8#WL2Y?2-I"CD&@/ \E/+L@0"4;K7H]*]5)F;+F;@LM.]Y9#&]1%H/Y4= MNB>FN.QM:H&7:J_2]\=QR5\)PW>S-[2C&2?2@D=[I03'.(^=@MR$_@()A]1% M\Y@+TBU)U!7KULNK&XOILH!A&BOX/>:0Q@6 9XBY(ZAS@9 )#\8N&98P4DL" M2T=7G15T;9U25":V-^.5DN7?"1W-DAL.L5]J%#NF*0C:>%[!_.(8K.> M71<2E*1HDU# 'CR:$=%)(8\F2!X'EO]%)DYGQ&>[)'?GIQ, 9(C I=P-64-_ MCC4,''<(<.TN&LOC<1M! MC@OYM"U$>VFRZ4*O-4,&RY.13NY>R'=ZH=!/7&MJ6$EPHB_N#*]@1-A- \S) M<.*_$S7DXXOK*F+T?IAM/I,*A1W%DT MHR9?\[&)069N=7-[>?J7YJ?A#WYY44]O3R=]);P,-(PHA MC5 $TU%PYP>>98@4/:AL_5&GG#K@<#FX>?>9RW#/!$]H0&R!HT'D\,PHSKCW M=)Q- )P:3'0MMR4-W39" =^">AF/-&'!/74_[?IP%]6)DLLPW'6BQR-Z,KOT MY*-]*^#Q-I7TDV_E@0);A%>8E2GE124%G,[<"_(S$?="*?HB*<+WPI]3T@(4EZ4\.AQS!WV!Q=[5GZTQ6U:F=Q+\SJ1LH/&_W#< M1X>]Q8=3QULB:8"3Y8(>[#-]R*4A3S- I'KG@R!P$,GY>YC=4=+/<)I7M010 M6FUE=1;I*LX$54QV7'V&FG1B]665FE'@"].$T6-B+<*?!X&H' P*/SD.0SHVGE)V:7>&BT*%_OJE M$_>5D5$K:%A!OK:6]QL(7;N MLT0[":GZ$KDE]9IH:3O&57JHW8:JXSZ46I1:E%KV6"V'&4@J&"CK5&I1:E%J M>4UJV?Q85JOJS5I_2UJS$LU::V=6O45 M*10?-HJK+3.N0*Q O U7?*Q0K%"\]RC>PX!B2V>YMEJQ?NUIQX<2I*7F@^\IVU3\U^(LA^LE$XSS'9[I MGD,%I:ZX)U(:+LQA&#T.3]/#KSD[X3%KLK/A]<7YQ2\W[.KLFMW\S_#Z;%9U M]7CWS$PL2HH)VS!!L46%EJ/$R$(TF%]. MEI]R0DH/0EF-L;:]:#%;@,],TK_)O*'LLV53;Y72()*B8CI1"SQ;G/D]R<)N M(A4B*WTJN[MH(I4]D&J S:9F=,S5<@YB)43)&3C9'P>I8Y\EJ^+3.%%"9.K1N:,8]Q!Z;B"FI/%Z3B%7%%R M@4BSF-889O0LL*\H\28IT,=TBBA^GT= I3SPH]"VV8-+**'!5>B:4E8Z@178 M I]3'0R?6;L@.JR 7,-617 Q!,"UET&ANEL MC4,_U0E20_4YP6:P*Q0/FU,FQ^57IZ; M+'S7^$Q29%L.F3Y)$WRFPPWN^UB5#WU7E."U"(2C>7+,)LML,/Z$Z3[QN:9X MT]0#O3"'YD[=0ASG47;.7:7CU%I5YN/TW)$Y6VE;9?G5,YQ*1H=3C%J+3\&E+?*2TK6U9:?@VVO)F 8,-(JC": MW"TD=I;M4"EHKQ6TV60JO7T[(GP1[P4V<.=%%,A:MH2C;D"K&]#I9!05AUPU M.5:E8'S8,!YT3Q2,%8SW'<;'%5_)53!6,-Y&4#'80QAO9S)1T>75G=R8KV(YY6OH?Y]]O;$W'L;KWQ9=8?F M5?$E[5ZCVZ_VYEQ-!+]S;2O0I4#7/JXV.4!-!+]S;2O0I3U=MZ- IT"W;4_W M>I<#%R7B6VF-L$[!\MEHQ VZ7!C?GLW21T.?*H4G0K? M%0U^W;;"M\+WP>*[U]MN@CN%;X7O[?KO:J?+!Y5B>?_7_J-L1-O9 W@]J?YV M1FD=UC_ZC59_NU&@RF>I0+[]E>7V=H=*!7(%\JV#_.1DNU=7%<@5R'?@R0\E M_;8ZTEV+(V;J!)Z"AH*&@H:"AH)&#<@X>&B\\B/=25H,2O><7LS=Z/KMSD]W M[>TAL_K8DSI_J*"AH*&@40OQ[%PG"AI[=;:XKL>(M?Z2"(TJ+VTQ%JOCW&;C M*[<[SBA2+7.MHU:U.R\UF: _CB@-?X%TZ M?Y#E4E_Y:NZA67JUS-7.TM4BDL+Q(41>"L<*QPK'"L>O%\=[&%>HD[&UF,BI M@TP*&@H:"AH*&@H:-2#CX*%QX NG)_E5TY,X=]MD:KO/?"9C&^-/AAV:W&0C MSYW@6=EI&.CX4R;+6^HX+9VC9?H$. Y\=L<-/?0Y"\;<\A@7^>$>W= VX2>F M.X'5C!IYY:NU=3DJM?$)D-9N[=_\1R%NCQ'7.:DVGT9-I+YS52O$18AK:WV% M.(6X;2*NLX:#?GY3^]#OWFOZ],/9[KG6,Z]?\6]&XPN M;X&V3S9$J3__^[\Q]J?_:#:C)Q@\PNB9!J-#Q,VF>&9>4_00A+4.\GO-1S^] M,;#^O-9J:8%+G]H=[0T+'4O\^KW5ZKQA)C>LB6[[/[UIO_D9-RKFTTH=5$5G M+Z:SMQ*=W1W1V6T-2LES5W3V8CI7D^=:>I>'5)91^CG..5>9[F4755*[08O: M!K6;P^L6J-T@:G/4TH0]-<,/]"?FZ0'/T1H]>$[/W>I/U_#4*5!J.2'T<#GE MGBY6%$J1WTV3WR'RC]/TK]SM5EE:B)\"EK23M5C*Y:F$1RPWCR>YPG/#O0?+ MX)&;XN:I.YERQZ=6+USG@?O0V/!1]TS_U@UT._W[J>L'%V[P*P=^#/?>@2#& MO*+NOKB>_ J?TY;J^>>K]J^#;_W/*=:W2F""B&CE2_8KS+)YASVS=-,-%G?. M1.^-S.\,^X9G O;, Y9TOS5%% P2.?BUT_!K]M[\W*.<4UO00BSP+\/S:_:W MX=?O9^SR"_MR?C&\.#T??F7G%S>WU]^_G5W7_3[1 \E&_8KA]Z MW(_#P.50*XJ_5UY4G8W6*UBWI:+4C*+W 67MV=,TY@(L8_;FO:1 MK2#.V1@[]?'.8^^+PO!J%J5_#_W &CT+9F['G.Q'=YY1A;YE +L"'VR%F"V.&[H^9[ICB _]G:,'[ MXB'=,,1JM,<-#E_#Q(.>C+^?ZL_T9> R?3KUW"G^D! M^PSM3.Y@ .]H#88H8V9(;XLW_+'K!Q/FZ % ]6CY'&!T:S;'F2\2?ENZ\)LJ]]I+6&V<]S;%+._N*[Y:-GV+"?1 M]R]2AM;JG&0(C%I;H]L5Q+)2AT-[.M;9)\MEWT"9OI^P?W\BZ_J\$ M40-M\-NGT+<<[H.HP?A]&N2'3Y;_&_4$'4$_43?0B^AC&9JUSHKR@_:;MUR? ML&_NG06NY&5\:&VM.Y?Z,!OQW)$5Y C%W\1/Y69T M>4MIMX^S="1-KTW*PJEPGI2.=E(=*8LF,WGE:"?5267A)"1'2J_7;R\E14Q) MV-NO\-,[L2.<3$Q8:D)TQT>NQ]D9 #AX!@,/QJ[)SBEDE .W; JF-Q@IG#T% MGNYZ,)#KWC,[#_C$IV ;>?)3W'_ MF^6X'E 6-3ETS&PK@G!!=XKL-8U@T.MF1+Q%RI4*YZFPG//H#SI*A;5382FG M>Z(I%=9.A>4&J_[Q<5U4"(V!T''= ]3YB3L@0QR M?51*;SG?V2M2VG8)+@>S0D>Q90F7U;C-3;P7?J=;?EC]&"XH(8K66+50[=M]U%W<.:- M*V(F?^"V.XV>FWKN[]R@Q1;'"75;'N#$S9-HUP07UIS_X M@V5R(+#!=)\]$!)6#I,CO$;H#X8ZT'J=VO'@X6=#!Q]]D%Q00!2M;3KR7*X0#0AD@L&%;?W!@4;XSF&.2T_><>@% MX/0O4CUI4&R'A%.@#WL.@3POT"TGDG7T1GPX6/[.1MQ$*5 [ ,2 %XD,7A:K M>M Y,N"*D1O$9./LE]9@802GS09J"0 #$J8&@L"S[D+$47+PA-V6DHX/D@:L MD:A'(6H, ,V]!P%8G1XLT$]N73?ZF#T L[-5]0SG>=N%'CW2G&\] 12<8 Q/ M.8BR_ (WRAR'3?8(D#P^ZOU(WVA')S\V4%93T;3]C'^-;/P+=!=9>*3X9,<5 MC7X>H1%@D$PN!U+0DFM8U-2C!;X"?J,5>]FB&7J1%9?EQ1V-T#SNG@6L RN- MX6507&%A?]&063 2-]B5:UO&,_N'_'>5T5@\>D C\5QP8S?8U 9/TF&3(7Y( MSZ1(EV&L56P5__B0\C"?"[P((LN68Y"%8ZK'XV$&?0GY4!PT+#!&C].X>\># M1_([\0Z7QZ>X0X"CCB.:QQ=I0)K7#^YF05\3KB/ P$_[D3UP1PR\R8!-+^N/ MOA@%:"'Z#BTIOIXQYL+'IZG$UM$8C2 :A&"\]?D1&Q8.7):?1!UHL]BDM6#( M04I\ND*"G*/Q>;3M)X>6(H]-A./+J<%*.)5*O )1>XI."]C1#&#;U" MU6XF5JEUI++ZN#'CW&?'#!I,V52W.W>BEY)WUA1QL]O)[1$L M[7-7K)734+/3'[R'L60UY@,,+>68H7)VQ*]'0T#&'HIFOJ0%U/5:/6ZLJ M<1$1=>&])(*U5LY-K,/\'$S'T=7G=[IYM;M9W?U]9X*.D_\OL;+^?A&L)5SZ(8]E3W MQ\OY2%[ Y]=4QT(NLCUMFY&2PY>F:4N44HZ=*YCF06@2[Q6@4[^D6%&<&%O. MGVPALDO9$+A3:D:TLB;7W>XR-[<*$3451=F!K;T, *5D(0[Z9](H9%,OO+5D M53*_:/O(XSA-I5/7$]>A4]K^4$XP<%2]=9.3VS#0XL-#S].=>_Z"HRQ:;K3H MMO.R6(N@NLIEX1YG3BZ]DP)[.4BY+/0C!7@I&)4/4BX+G4H>+[T"G[(9N20G MD*47;3"<9K\]>XJ.S$=G00O$DCV\#._%;ZUW(+F=FQDM[VEW'*UPUKG?[[^< M(3PO3NNC]_!+P2@G8KSGZ#%\'QN\'%V+W:DB]"TG6>OD!O6E'55)\@JX:>?M M9'62XV=7/^4@7U"G'*"'S%VC\XN_G5W<7E[_6M_3#H8[F;H.^688$ZQ8^926 MRH>><&E:C K!V U]"#;]=Q]>QD^<;T$LRX@,"P;',V5O0+:>R;V?WH ]&MRV MI[J)3B#^VY_J1O3W9L0B,S0,6C\FN%DGC9FDN"G^_L#:TZ>XDV[_QR7)'C;; MG[9"=X:+0G7PGG/9KH6NXI[_D^Y$MI "YKNV9>[ $ 6,9$&+U!YV=695@B!T M=Y7F'RG$PJ*D) J,V]+]GT.'LTY+ ?$E0-QLALDJO/!+,-XO*];=(OCM=T>' MB#S@YKN=)5':-DQJE8ATL*2 T[7^R/"$A6?!%."5)P;=>.JP@RZWH#7:'96+ M3P'Y (#<.>GL'Y W-' MFWK6JI[YLM$LNV:V4= NF:5L,4_\TDE+71+:ER.T M!C5(VXU>3ZO7'&>+ZE((/WR$PUC7K=DL?M= MXP,QG!=FHE]T,B!_WH".I\P]7%!\'V?Y\8TV:*'X+$3VELO+B5@EB1KXT.5$ M9)9QY]( 3WV+'MK$Z9:3V:-FR_JICMZ5CD1U9D\0K4SO^<7MV?79S:W,0U%$ ML4A;(ZY#1;ENULP[D[MJ5=S+QJDLEVWF9$=$ECI3K.4M>2M4EKP:4I+*U#6> M!CL-/0\>G24U]8Q\XD76T^^<9 \4YMO=.%DK.*%>K_\2LA90\R+I#&:/K!== ML'II_ZLI4 X&30FZO6Q51_=T*\&6WH>/8L@-@ ['=BD2VS$:?" ;A/KM_SYJG'32M@ MPWN/T\'BN=ELOUH.OQR)Q[] LWB+7?1S*KLYC3OYPOE5W,4RW_G;9WX'+B;* M]DTY<$4W,5%%*7 S]16Z5%^AU>ZEA?5">I/[F.)BNAL&?@"ZQXCU1=(JQNP+ MV<["I)^Y>97N]&5Z2#>U MZ9$\;GG+8SFM7B[S:O.)BR5S0?5]4/FII-V+[I:)%RY')0KB[?N-LLP-+7&I MC#79Y?4OPXOS_V]X>WYYP887G]FGX>E??KF^_'[QN>!B0?1QQW?+,/<9):Q$ M"PBC0^2H01-O^M,G.F)!&<*2C'Z434S<%Q85JT3ZUN2!P-,=7S<$(#*UJ0!: M>-]WZE.N3-NBI&JGKC<]$MG.,!,>3/;!][N/F&/0#^]\R[1TCY:YR@;?1KT/M+5>$ I5K#J#*8AI.R';[_[E'[PG:P_ M@"8P%'D,Q8JJ6U# (.?^>( -1^U^>L9&13H;:C%IEW%&Q4W)*VZQ4GBU3X[[JXAK16KV3UPE][ZZ,ULW&Q27 M2 M-F5=%,MU\$59X+"GXL6X]DD'.3I*V-TM8R8R=G:T15K(45O=D:Q(K5^!) M6T=BUQP3R8)AQF6^WZ8*/V*./PNF#^_F3I%*Z?ZWFRBJ%+L\IW'B YH61;1$ MI*Q4+G ]P-QZE'_ZF=$6U%:XC+JD'E=B\<7<#4V3EB(@]L2WYV P](PQYJJ=I5CFKO6_ MN-YU_-3E*#616-=?M;,"7][A-GDI9X=4.;ZVO)3SSK5EHV0YXY>K)'H4:TC1 M&1>/Q\=UN,QJC(< D67Y^US^;EWY1-( 71;"EZ-WUPU79K,VE^F[/DR7\QY5 ML OS!!B:<$_ZRM:=H!'?'*"*NTN9C5ZGEX>.&;^Y;MGHOK98O7,[K@>W);?I M9C:!7\+MDGH58UFAGQTQL](63'L-9ER#<]-G(\^= M,/[$/K44]C=MKDI%YC,9/>O'S<;@UHMV"D7_+X< M:M>75V?7M[_":/IU>'%+1R;/_OK]_.K;V<5M TN1%K!2/(Z]]-)_MSU3[&)1 M#ULC?(7AL7,\LTZX$N$KE,U,?O%5#>Y-U. ND#F=7EQ((?=1=%E8 MP!D"AONDLZ3<=*8V=9'(4=(PY?;NA9A)IDMXC84?22K6E*R-+FI%QUVD*XZG M"'3,]]!\HDG1?+KP=51$VF4Z/&)Y)DC'HRL.L7CT>^X8ST<9Q6$+>BPX$#C6 M_$9LII1A\Y2$EI[YG>^O4G<]Y/XZC_?7]=3^NBGWU_.>,+L5GMJ3EUOR+_+< MN6JRR_O9!2>K3+([K9XNQ0B0TF$X]UPQA'/%U6R;) M\*-;%^0L*1LR^6U_;$VG.&QX-#8^3IJ=Q>%RM(@17($M@X>M#].]Q" M@O'&CQQ_-"+"\&7P:4#N/QB[,'$6M#Q8.@-;"ZPIA'2R1_+P$?UZJJ#>D3C$ MX-.\ 5LR('($TX6'[\!:02X1HQX/0D_>WS$M/QE1(WH$M])?<[&232=H\'5J M'TL5$HF6&$Q\?4)9.? FH!B-A/.2,O5H?,),3/1A(@@ M< A/ES*DB,*TH,6@ 02(3\2-2^M!$$?] 1$XCEW@GT#WN#@$]#]R&!?A7_D[ MWH82=S8;\K83[@E"'(:ZC(;HNVL?<)DKG:BQT4'C0!?J,O.;!S.Z27<]JC%J(Z4E*?(+^3 M%7MHT *HB]5>$8WP";VCYX;W8\$TWK\$M[0*ZU-.N6\8S Q&T!=M,- &H]QL M /<]U6'V)^4P!?\UT0T>4@)+;$_>:T3O_CAVX9E1(LJ8Q'0K%K('3NW>);\H MO@9;GN(YRLA7'.5&\/K=B#V5 Z$<_WS!NW#N068>\Y ,K>)AND&>%&J,D9IR M9.X##CERE([B@F?ANB"4EY<\,?BB[V^>_8!/I+_I'K<_$H8BORX&L$0?MO6' MN()[J__!AX_Z\\SETFL:RF6C?KK5S&S.3[OM;[IE8S[2S+U0)")]6U0;=#^R MJW RI5]H$R/J[)/[A%*?WP&])A[.W+*EI@S=B=<\ *?A5 1#Z&)\#D,V6@2W MA4$W$.$X6R%(3^A4NCC,*ZMC?F!OM71/;\MO,.1V==I!N3;B8W::T'M,\="M,\D[B-EUHH_*(* MTQ#RQ%$-2!"B2].UW?MGC%%3 4SV.1B,4XM!%/W!2)\*0*4E_!/"'"!%G'2( ME!?K2\:/T.SLBH\,D @&ICQE*A&,2##*I%_^DP MTO)2 J& E-BP7)LF&>D5%(X3 R??9^1Z M(DWX LP92E9#=39PCD+]S&PFFI^DHMU4HP0>E*7=$'D Z.4O'!5D,UM_Q"#: MQ)@+GP9A^P&&",CZ)'UK7HA&WB3V.&U52VOVZ:9[I*AH1(E$";1,4'G/Z5@= M8V?,P9=B6>RMZ]/XD-=).J(? M4BN$TD3EFF-1\"RR.^#T4TZ%T(.(1"79I6EVNP(Q%DYU+'MFSHT#-ZT1@X]R MA%V#3X,1Q3)BE'LS"^Q"*I:!A(]:,Q!8A"E8Z$"*<2 M]'';$'E0UAH4,DP1 8^3[)(Z"24SS;/("O,.2HZ=!0XJ&E4I@,%(.I)F[""D M6L6LBXI2@SPP+<@*=M$H&DKSWI&&%ADXX.!@2X<74>#Q1 YL,C#&MBR#7%I M$XAB>35P,0A:U M!)2D&H(@7\_.B]"@,D1A5!FOUR3)36D4M>UE5B)G%A.(#N6JO[#WK 2'%"< MS'!>HD=BB]2Z4'D9Y*3 /XL7Q,E*J_M+%GIG5Y0+<\/?X$@N'RC:<"VWWWW< MGTG'/M/\1D@J>='EY*1=/4GE3E@.CF?.X%5!4\GCT[W!S G7>33=&&-NAL*5 M72'Y?+VS+M5&-&#&?,C M:A)B!"T1*4/'3&=/%G00%2MOC_Q6D*Y.W$A$TH%R(#RB&\B.TK'MTYX*U=V( M%_[%))%"TDFT#SL%9TW+)?B[#C.#!]T.X\%-%_K7T_JWTQFTA=QS.QBEYX5Q M+1(QKQ'51T3IYS>RY IF'84QP;9EM9'X;Q]SN\F_-R-"6:ADT/HQ4= &RCGW MCO>L_E?!?OU&:^FH6KB'70NWXO*7=2Z$N\3D:USS]HF;TN]OT=8KJJA9D\*> M-2O;.6C5RBRW69YS7T?B;/\ MQ75-/%VJ1LK#'"F[6J=6-KG+2M;I NY[-W[&,]FI_BR6&$2N;B_DF16-C1KR M(@G6HF;OG,KR.QR3RQ%:@U'[K=:J=I);"*)ZK6&\6R" BIQ1=P5G5-NHX=;% MHTI1J@EQJJ%2Q[-"L?"*QO,*BH57.^+7OUAXU6L#U2X.;*14>-DPJ$RI\ UO M0FUGLZVH"D;==]F 9B194*SVU]3^VNM;U5/[:VI_;:WEB7:M5B?4BJ':7]LY M&36(H?O'M3)+M;^F]M=V348-!LM.S=;RU6BI]M=>_4C9[M?*)M7^FMI?4_MK M=1JUWVK5>@BUO::VU]3VFMI>VQ+_6J/5J78:\FHWV.*Z@E,NZTS,W_F*GKWB M'B;YX)]TWS*@L\^6'09E=[CV:\LJDRXCNVME.7C/6%QXM7SF<(/[OBZN\0/2 M#,IRF&1EC.4D'H]Y;22KFA#_$@T"/SNL%S3?$FW@5^]Z%@ MPZKR!(/+Y\UO(CG8&28'JT$8JW1>J&EM+R^EKM*RZ] R\J67X.6ZV_+FPD(-HRD"J/) MW4+B[7='#TTKX.:B?:,*MM:5@O9:01L^:=3>LP,,F'?/HK+S#5': W,_+EO" M.?C#@#7?_ZO9685^Q2%73K&#F.N*0L,_<,/ #G:IVOO)EU8.]8ZWU&MU]3&.L0+??H&L?[V&E M"06Z_09=M[N'"244Z/8;=.WCU[L8 M;QNZ4RK?N=$0^069$K9[8WF-3 FU(+0&5XM[)W4X\+D;92E\'SZ^M8JS72I\ M*WSOU']77"U1X5OA>[?^>[N)3ZK#]S:2+NW]VK\I4JEL:0_@!2F9MIMA;9V4 M3/6@M [K'_U&J[_=*/!%Z9,J4I@"^:L >:_1;>]!CC %\MK(;"]!?G*RW:NK M"N0*Y#OPY-76@M@>R-61[EH<,5,G\!0T%#04-!0T%#1J0,;!0^.5'^E.TF)0 MNN?T8NY&UV]W?KIK;P^9U<>>U/E#!0T%#06-6HAGYSI1T-BKL\5U/4:L]9=$ M:%2Z9(NQ6!WG-AM?N=UQ1I%JF6L=M:K=>:G)/%7A^.!Q7*^[, K'"L<*QPK' MKQ?'>QA7'/@"[]+Y@RQY^,I7?,EG>4L=IZ1PMTR? <>"S.V[HH<]9,.:6 MQ[C(#_?HAK8)/S'=":QFU,@K7ZVMRU&IC4^ M'9K_^8_"G%[C+C.2;7Y-&HB M]9VK6B$N0EQ;ZRO$*<1M$W&=/2Q)D JOWP?ZGA_ZS7M=GWZX M,<;<#&U^.3K3/<=R[OTK[MU@G$D'A8>.*3?\;['-6Z#\DPTQ[,___F^,_>D_ MFLVA#7_J(G&73^F)19!ZI_LBF=>4.SX%M"G?\VGJJ5-HY8L;4\#-*_UY M N'TT/-TYY[C1U_V"4]?CI('9UOQ/SU?V;J3I1LH9;3VP"+XYA1N#@ M=. S-_CD#N+]CM9@2!D]!A^Z#3&#:.:E&\\*:(;@ R4@I$>?O;4>U^$F=1'PA638!'$A^WDY49(DD!7,FTN4NK]%FVA^ M$[9PAK90J1\NG0%2(6%;2+BQGO86!UNH7J#JC=AJKC/I1:E%J46O98+8<92"H8*.M4:E%J46IY36K9_%A6J_L/ M2Q/'G,KS81Y_X$[(-UNP?N?'%M5-[VHO.JA[#@K%>X]B=9!=@7CO0:Q56Z%. MH5BA6 44NSS+M5_Y[&^X;0,W#7;/'>[I-MV5T,V)Y5A^X.D;O_V\Y)3"%K,' M+#VT4)G6VUT MI_"M\+W3^*1[*/%)15.:[@I3FMK64+UU ]VN=,[27>X3*EKAF&-J0! SW?#. MYH>]"%*2_1JLD[2U[;J:[DM<345@56:CS.:E,ZRNILQ&F8TRFY(3MUZUFTO* M;)39'*#9M'N'$J2MG<5LB[G$XAQH^+3K8&MXOLUR'N"CZSW/3WAV'CUR&GH> M?*I-CK(*)L"_AWY@C9[EU';,Z4)5@;1>3^*RP582E_75!>UZ9(=1V0)4MH"M MZO[/H<-9IZ6 ^!(@;OB4?@5>6-V!WQAVZ@23O=JBN-8?X070EZ7;ZB)'K6>S M-9NJ:HUV1QV#5T ^ "!W3CK[!^1MG"&>,YKM[ SQLM'L"YX5'G.3W;NNN=GA M3)W&>06G<1J]WG9W^]1Y,X7PK9X7;G2Z-9O%U_K$V;Y-Y]2)LX.-FO=O,[/3 M&!P?RG:F,AQE.-L[!= 8= [E^,S:YP 6;[''6_.+5WX1+PP=ZO5?L-,;E@3W?9_>M/LO/FYW=5Z +<4 M9ROUN@.^>C%?O57XZAWO"U\SARX6\]73CK7]X*L;\[4*#KO@4M;A:PBN1+_G MC#]QS[" G*EG&>EBUGC,PW1M6_?\Y-MW.5X+3^:DS_%\>LX?\WG4/?-2U-H^ MD_W[Y\X5>$S7_#MM1'%3$AC]?D7DE<)")RVS-D#\:#!(R6NKE!^8W!=B-2]W MK:WDOAFY+QJKE-RK\S.+QM)9N7>.3HYW+O=EF=)7$_":@U2[-\B.486=5$US MN8"ATSO>*,V_I.*&[)#,HDC@']_HC-K_;8:_W\X=((3?!'I ^/HJC]$.GRS_ MMR7A@2!DF82ZK7V34-9\*Y=0N[59W$<9.F]T&R:;6Q0&=GPYHFY78ES;-V3, M#*B5(T/K]/9-0EF/7[WM=&ML.V7@4M9V^C48*LNMA=#C=555F5&QM)O;;(BP M68B6L-<=N_>-C%_+W(E6SIW@SY+F] ,-)J)Q^2S*]>VC&?V M#_DO+F8R6LU<48>B:?":<Y.-=,O#M?R0HWWCCSK.[ A%T*3'#??> 89-O&"E)V6L7)C:T>-\,K7=9\[% M>OPQH/DCOO;/T/*M@"/G#W(Z#1-#]E8N4MK/]/(#!V$[]]&OD@)\.7@6Y+\[ M6F'IOCQF$W,"I5LCRT!)#0W##1TBB)ZRT-35Z,T#NI.WY/A]QF(N M+F_/6(W;'AZ>OG]XO;\XA=V=?GU_/3\[*;@ADGT<<&E MO'VV]VM1O(!="Y-:8.J;I:) ?438AV0'C578?7QY$VU3=YX3E^)']1S8R',G M;.JY9FA KQ1CH/^1OL-GCV/NB!.6=-73'UO3*7HS#X92&PP;?%XC>1H:>K!, M_ H;":P [V_")\_R_T 78[L^/*3#_P6N<(< 8A /'!N!I\&P!^Z-A>\G*#E MP=+9)+0#:VKSINR1;H5&].NIM;(C=H7]^[@P1BT9W MTRX&'[\#C@EPB1CT> MA)XC6#4MGQP(T131([C5A6M!7PVMZ2@U?)W:AV8%B99P[+X^B5TM_NUQX>6E M3#U.TO= .$0FD9%T30X7/3T\EQDO NY-Z,IMFE'V: 5C>!M:#!I @/A$W+CP MDH?GB/[@ 4@:=X0MT'T S /]C]RV\5_Y.[A'DZS!;\CBB#0B>*1+ US[/1!R M]RR&/-"FZX&,KX4PB50<0R;$9DPTNEQ/-X(0)IY$?(.-8:[G>K@U36.89W$8 M%AHL\#ANESFZ_>Q;0A>@G]^!$V@I1V$DYP<=1!Q&+/B$/9!IRJ)NY+BGWWL\ MDM?8,L91_4>FP^#GF"Z*R='OJ1YD=)T9" !53.)'A?B#,0SK$\[%V!X-M^W6 MQSO+%M/K,=AV_+WVD1F>1?=LQ(X@4!E"_Q$(Y*A.IH4-TID%'/)1SC8/1!@A M:)ZZ%K@#84EC: ADZ_@C[I'=H:XY->NX"%:P(-W!$3\Q ^I_(D!&!LQ!*O>D M,BE0Z1PR003$(1QOTJ$8;"\1\U3RAQBI M*4=&$Y)HE([B@F?ANGSV%N<(4Y^"+_K^YMD/^$3ZF^YQ^R-A*/+K8@!+]&%; M?W"B\5;_@P\?]6=VYCQ8GNN@SD&OUS24RT;]=*L>%WX250J>,^6VO^F6C6>< M_+3+1B($J=(J!MV/["J<3,7ZJ>^#^Y>=?7*?4.KS.Z#7Q,/I/MY14S!IP7$- MQCQ:V FG(AA"%^-S&++1(K@M#+J!",==S@ZZP'9E70SN=E@/:!] M[E"8YIG$+05&U-1(-(88 BABV0X H?(N^@_'49:7DH@%) 2F[-4964@8G$^"Y X\G9,^7,$ ME.@7L%R;)AG!V/),BD*?&<>)@9/O,W(]D29\ >8,):NA.ALX1Z%^9C83S4]2 MT6ZJ40(/RM(&V.&:*+W\A9NTBV+KCQA$FQASX=,@;#_ $ %93T87;)-$(]=7 M:#W&BZS9UT<GIWS!>#1_=0L$>:%(7J! M:+;H/D)O.+QG,%.,QBQ-<6@=]Q7-^%;!4:*.Z >,O.\X3YFH7..I@\^RA%V#3X-1A3+B%'N1F![+AH%4/QI3@"A4Z4B(<"I!'[<-D0=:"PD9IHB QTEJT302 M2F::9Y$5YAV4'#L+'%0TJE( @Y%T),W804BUBED7);H">8#QKV(7C:*A-.\= M:6B1@0,.#K9T>!$%'D\$D .+.!9-+=L0ES9QB&+8(\5*0&#<=%2PDQI,C651 M].WA1-"7ZDE-P5.3=9J@9[#P)?0P/)NX&(0L:@DH234$0;Z>G1>A066(PJ@R M7J\!_G'=&+T>CJ*VO\S\NK8A<1 O0G61^V8 LE/;&.PV;]"7T^KN(0H*UX/)L% M;3RRFQ9-7!RTE#L>/**[&%D. .MU..DTV@$AN;Q11&*S>G'$6MN\?Y-Z$>3 M?NX(KXC->&+%"U^&*$# ]1'7?@!I@%<.1!E!,NJDJ:1ELJ>I6-4"AXQVZ?G\ MB UI[T>"#6-Y0C?8#KA1B/7$W79JTA);3&!T-!NB#1QP_HATHL1'Z<=H%J&J M!+59(&LB/#83'4,U\XC<2]RSF%N/<*6L@$89TH#1I79P?@_-^]CM KD6&#KQ M#"-5-+>+8[PCF$(%N+CE6S1VX3L.+DOA'U&DF%FQI'6RN]]I78$"))PR(A:E M,I\%QR"-Y'5:41,!M@BJ(T1%*M:G,"I!B DD.>#!Y.@D?,0[\A%S7S/:5C#K&&1.B!H!:H"+U"U>)$U)'K M?4(:.],>1<*/G]JGEK*I@0 "[;LP6!#H'N[FE=S?I 44B#WI6M5R M)QN_Y<5OQ8L.@+X)6*1-:HT6A\V0S\2+8JT2H>9 , +JO4/GB':B"RO,!HI+ M.K_3;3UVB.FAGX"(H9CSSQ#]1^Q%)8PMVC$*B,#L5OKL3D,R^X_"_GF3S0FB M&O[GBR Z,CF$UP6 4VI&Y^L+L1C9Z>!H7(F<.]N':^+65>""]D'-)-+$1 MO0-_BPA)^#)<,D572I,?\)YXW1O^YK1Z#S82=Y8X$G\VMIGM&"4=[>)(U2[C M-19^)*E84W+4$UX@[B(]EJ0(=,SWT'RB2=%\VJ6E5LXRRP0I\4#XYQC/1QG% M80MZ+#A<$@-OCMA,*ASK9L[&S+2F=,LB?:, 0-/3 ZNLQ"^P,0 MQH3!&&9"_^+15ESN- N^>AV_>25>',:O#>DMK>"TVY(S;KTW/W?$%>@46ZMU M-L/7N>^'N-TE%KC$79,&^QMJN"$@) _!^2RZZU^I_5;?)[QC#2>)/J6YQJ1*&IYI7.-LZ(K0^HFA'C- M::IKLC/=P\C59V\!CN%$6AK,I@"0P;L*Y3M[6G:Q?"-Z(W+W0LA5RVS9K1FM MD[?1;I3"S[$ZLL)=1VKUSHGN[?Z MW8="Y02N0J$"F6T9:,E,IU@0+S;<5,,YPG9HJ/-G>GDRRXJJS&!1H7C*#PY: M^WC1''A]R6Q: KOF9_6Y0(5Z7G>FODF!;&3HJ5!6&QEJ-BFPK;C5[^.UJUVQJ/3"7S"CX<@7/N5S.4MF@\"Q%^CF9$(I1 M1JCH%KK?B(-YNL$@.EMK=8_Z]'>PO*>EY=N"N$=K=]N]I9.#!?1N3=[K+:Q4 M)_&E3FM6YLOG8G40][;@O=$(=E;4?4UKG>R%N+>'[@U/#?<3W14XC46)4C)" M.K_X@HYWE469PQ35PKQ'!:)JM7NO5E2+,D J4:T<5Q89X.8BGP5KP^+]!L35 M>+>)#G.)QZ60?O%H?6J]KB/ 7((W*-CUHYBJQ%HRDNFU3T[: MKU2PE*VDJ:29]8YVT;IVY:? M;5NE_Q6.\4WG#P6Y+H4:SITOKF?P N9F\U!=M7]=QD6VR3([?=69!G6P(Y>S MQM&?]3S.2E*M9Z>K M62L_6HDPRZWIUT<86S7JFIQ\W()8MQ@!U>7P\ZN)@.IS=^&01Z?MG<.H8'1: ML( MZ>T?M]JS:TO[@99*E]RJ1L.NI+; M5VMJ"-,K<\__;R;LF5VX 6>?+=^P7;R:OKA40*H!\3J^G;S\>JH%4)WGI%3 M"6NRL[]^/[_]E=U>#R]NAJ>WYY<7-2T/('%<-ODT/2;2,OMD&^XT2?,;K?#[ M N(R3>! LQ/9YD[L'D!HZ@4!!A.\YLPF#,RF.HLN01= M::O-I>7(Z,9Q'SU]^M,;\6]I_11"(^=\HGOW MEM/$/SZPP5$;VZ2G+ >S[WY@3?$E$1/ER8G7_1:KZ<4(7RJ4S9G5(BSLB P/ M;259@MPR1JA%36M $+ S(]RBX'>N;06Z&'2M1KNG0*= MUU/UVYTV]5.+VLB M^9VK6Z%NWUW==N+?$?VGAO'OE>>"E$R?O:6RT6[HZX[I+YFL;-1*,Z+9G956 MIB%J\8>-"K2TZ5?+7+=>8TU%@%(H/FP4MS6%8H7B?4=Q1^LH&"L8[SN,]]$9 MO_*5]"'6LK]/3M#*&N]3+.:+!W%?^<+ZH=E_M#!2.%8[W'\?[Z(]3,XOW=)DL_JO@PEFVD;3=_?H2I^7Y,$0OV4J%T?5A-,5YUVGB66! M\<*>*#'_.+:,,18CC@MZBU+DJ=K$5(U89^((%[XIIRXB$R 2UC[JLV>N>W6M M-'WIL#_K3JA[SVQ 8NXT,N6]=<ND@T"^Z= CZZ50)WE. ML1FW ((%*%'?@KZY @C&8+'WXYA] >O!$=O U55Q094NGGJIR]WJZFG%]Y?B MXZ2#0SMKFMFKD/NDF+IW:@[=&4HRZB1,O;*,G9PU_3ET8NZ6JB$J^YM[N:TB4Q?F%HU MV]*VQ1YM#1WL79/^<:/5WL-]'(7#P\)A4T%005"YPET+7N%P]SALGS2ZW9/] MP^$KO_YYJOMCF,-;)G3K1?O1Z:WH"J^%EC9H=:UCWZ]U]+KUNB&^!40I9+\* M9-=K*J!PK7"M/+9"MD+V@H0U[7K=,%-W3%>_8RJOEN*\I9K[I0>QV'!H_J!: MY@9')]5NE==^X4A!^T"A7:_)B<*UPK5RV0K:"MJ+J556_S%U7M;=^@ M3*ZJWKI8.[U@NP,XAOD$7NF+KO_!(ZS=.VFT!^WH!3U@.C-;>9/ZZ8IH$/",U]5GJ M7J$=,_UH!6-FX.X/_.7"$SQ_U37Z/%/?=96:JXO+O Z#P+/N0G$Y,7#9%9 $ M2EU:X+6@DFN_TUI26;[=Z1WW\\7E,PUOB]Q\2=T\N=U>KUT%N67*ER]FH[N) MDO8YQIO]8ZT>:NJN@BKMI-6M@MQK'@@?<*9[CN7<^^SMT##"22BNO'_F(\NP M@G=5ZR\B(Z)B-15J[7ZO"J&L7E]^?I*M\RF MY;!3?6KAN%6Q )*>L>-S1W:[DC#:G?Y))>+8G/4F,US)*T$KS!&U-&4M@.Z) M!EXJH:N@V2H(R\\&9PEK]T[:@_9JA"W:&Z5CG*9KV[KG)]^^6TCUT "->-R4 M[9ZZ?G#%/>HT'U;"S$T+7/J48ZHSP]0\02_HL!9,]EH#R62!YC),MB$$.#KI M[BF?W9C/9KA66 M3&8G"@O(^J3[ED'Z%\N5.:7_7:;NDS*_"''XN1P)EWB9I)$3#972O)8/;+K] M08;R4KUOBZF%/KB J?;,);F3[CY(7I96O1U\B:]%^^Q M+57DST5;J>6R9:0V7M_,[-^J]*U58U*?ZH,]_ R;2JEU% I MM3/70\PKJ)(\UD@9>Y7D\="5H2RC1LK8*\M0Z4\/*$.G$JY*?ZK2GZI<:QN_ M&Z1R_BDTJJ_2G^J$HY5Q9S*I:>@?:#0KM?D1.%:X5JY; 5M M!>W7F?XTR:I9ZK9?-EL,8FL9G_(E[AH5;%8$;9_IDAL@3Y(L\04NN&^)# MEZ*YLZBU6_=*MI5* U2;ZX<5S,9^#_W &CV+;C9PM3&CI+1JY";3@@RO&>71 MYIJ9,57-C;87ZD#HOU#.WJ=OXE9!%AUIZD$6!0V*[J*JI!9@Z/8>^NZ MVX=F'GMXA4GI_I7>F%*Z5W:O=/_Z['X'-R5?UG2UD;:Z)JC4=H!J>^7G/"YG M%WP_W=!7J M]AEU>^KJ7OFUS"O/!2F9?I77+]7]AEV?(*J6N6Z]QIJ* *50?-@H;FL*Q0K% M^X[BCM91,%8PWG<8[Z,S?N4KZ=&-R6@E/;HZ6.X\% X5CA>/]QO(_^^$67'5]XUS"^_'CN&%@U MF&/E1O'!',M@ ;YEPC0-40$]]DFBP16[W!EKY=#Y4JYN/=WQ1S!U=D>, MP\]3PB"P8SD/\,GUGC/,1(]?CLZBAV_=\^C1#?&PN),MD5X.65JKGR!K1?JO MP%?"5[B4@1R *[?H^JYA@.,._)0CB$''15+;.]?SW$>\SGP'=MD\A>^M@ WO M/2YCKU%/ MM^XG_BWNYCOV\B7JY#3JHZ#Z]LLEFP5I[\W/ W$_08IW+4*7@=A*VU4ET(WM MJ0:([2U [ IT+@!JH#M"H X/V*/K!>/*$7LKN[S@P=^QPQH 5VOW%B#W103G M9(ZDLAON/>!:,CY&:\S7.(*6DR,V)-N)FJ%6MH'&\XLO(*TCK9>5U#R2YECQ M%4@1(Y*A#7%Z%-ZD0Y4HMF=7N/+^ B.6/<0=9&*3J'5J?!M2:Z,-#XJ,>'4Z M8U'"R.3>.T).(,M/EFU3#I&Q:YOLF@/\PFQ@GWKA
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end